| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | structural constituent of skin epidermis | 2.52e-11 | 43 | 28 | 6 | GO:0030280 | |
| GeneOntologyMolecularFunction | mRNA binding | TARDBP DDX3Y NCL TAF15 HNRNPA1L2 FUS FMR1 HNRNPA1 HNRNPA1L3 RPS2 HNRNPA3 | 1.03e-09 | 694 | 28 | 11 | GO:0003729 |
| GeneOntologyMolecularFunction | mRNA 3'-UTR binding | 2.94e-09 | 276 | 28 | 8 | GO:0003730 | |
| GeneOntologyMolecularFunction | RNA strand annealing activity | 2.46e-08 | 5 | 28 | 3 | GO:0033592 | |
| GeneOntologyMolecularFunction | annealing activity | 8.90e-07 | 14 | 28 | 3 | GO:0140666 | |
| GeneOntologyMolecularFunction | sequence-specific mRNA binding | 2.36e-06 | 19 | 28 | 3 | GO:1990825 | |
| GeneOntologyMolecularFunction | telomeric repeat-containing RNA binding | 5.68e-06 | 3 | 28 | 2 | GO:0061752 | |
| GeneOntologyMolecularFunction | structural molecule activity | 2.13e-05 | 891 | 28 | 8 | GO:0005198 | |
| GeneOntologyMolecularFunction | telomeric DNA binding | 2.36e-05 | 40 | 28 | 3 | GO:0042162 | |
| GeneOntologyMolecularFunction | molecular condensate scaffold activity | 2.73e-05 | 42 | 28 | 3 | GO:0140693 | |
| GeneOntologyMolecularFunction | miRNA binding | 4.09e-05 | 48 | 28 | 3 | GO:0035198 | |
| GeneOntologyMolecularFunction | regulatory RNA binding | 8.84e-05 | 62 | 28 | 3 | GO:0061980 | |
| GeneOntologyMolecularFunction | pre-mRNA binding | 9.72e-05 | 64 | 28 | 3 | GO:0036002 | |
| GeneOntologyMolecularFunction | DNA/DNA annealing activity | 1.03e-04 | 11 | 28 | 2 | GO:1990814 | |
| GeneOntologyMolecularFunction | G-rich strand telomeric DNA binding | 1.03e-04 | 11 | 28 | 2 | GO:0098505 | |
| GeneOntologyMolecularFunction | single-stranded telomeric DNA binding | 1.46e-04 | 13 | 28 | 2 | GO:0043047 | |
| GeneOntologyMolecularFunction | sequence-specific single stranded DNA binding | 1.97e-04 | 15 | 28 | 2 | GO:0098847 | |
| GeneOntologyMolecularFunction | protein methyltransferase activity | 3.98e-04 | 103 | 28 | 3 | GO:0008276 | |
| GeneOntologyMolecularFunction | single-stranded RNA binding | 4.95e-04 | 111 | 28 | 3 | GO:0003727 | |
| GeneOntologyMolecularFunction | mRNA 5'-UTR binding | 5.58e-04 | 25 | 28 | 2 | GO:0048027 | |
| GeneOntologyMolecularFunction | structural constituent of cytoskeleton | 7.84e-04 | 130 | 28 | 3 | GO:0005200 | |
| GeneOntologyMolecularFunction | single-stranded DNA binding | 8.56e-04 | 134 | 28 | 3 | GO:0003697 | |
| GeneOntologyMolecularFunction | methyltransferase activity | 3.22e-03 | 213 | 28 | 3 | GO:0008168 | |
| GeneOntologyMolecularFunction | transferase activity, transferring one-carbon groups | 3.71e-03 | 224 | 28 | 3 | GO:0016741 | |
| GeneOntologyMolecularFunction | histone methyltransferase activity | 4.44e-03 | 71 | 28 | 2 | GO:0042054 | |
| GeneOntologyMolecularFunction | N-methyltransferase activity | 9.47e-03 | 105 | 28 | 2 | GO:0008170 | |
| GeneOntologyBiologicalProcess | RNA splicing | TARDBP NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 8.10e-13 | 502 | 28 | 12 | GO:0008380 |
| GeneOntologyBiologicalProcess | intermediate filament organization | 7.03e-12 | 75 | 28 | 7 | GO:0045109 | |
| GeneOntologyBiologicalProcess | intermediate filament cytoskeleton organization | 5.16e-11 | 99 | 28 | 7 | GO:0045104 | |
| GeneOntologyBiologicalProcess | intermediate filament-based process | 5.54e-11 | 100 | 28 | 7 | GO:0045103 | |
| GeneOntologyBiologicalProcess | keratinization | 1.65e-09 | 87 | 28 | 6 | GO:0031424 | |
| GeneOntologyBiologicalProcess | RNA processing | TARDBP NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 HNRNPA1L3 FBL HNRNPH3 HNRNPA3 | 1.66e-09 | 1500 | 28 | 14 | GO:0006396 |
| GeneOntologyBiologicalProcess | mRNA metabolic process | TARDBP NCL TAF15 HNRNPA1L2 FUS HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 1.35e-08 | 917 | 28 | 11 | GO:0016071 |
| GeneOntologyBiologicalProcess | mRNA splicing, via spliceosome | NCL HNRNPA1L2 HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 1.75e-08 | 358 | 28 | 8 | GO:0000398 |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | NCL HNRNPA1L2 HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 1.75e-08 | 358 | 28 | 8 | GO:0000377 |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions | NCL HNRNPA1L2 HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 1.91e-08 | 362 | 28 | 8 | GO:0000375 |
| GeneOntologyBiologicalProcess | mRNA processing | TARDBP NCL HNRNPA1L2 HNRNPUL1 FMR1 HNRNPA1 HNRNPA1L3 HNRNPH3 HNRNPA3 | 2.85e-08 | 551 | 28 | 9 | GO:0006397 |
| GeneOntologyBiologicalProcess | keratinocyte differentiation | 1.74e-07 | 189 | 28 | 6 | GO:0030216 | |
| GeneOntologyBiologicalProcess | skin development | 5.10e-07 | 373 | 28 | 7 | GO:0043588 | |
| GeneOntologyBiologicalProcess | epidermal cell differentiation | 1.89e-06 | 284 | 28 | 6 | GO:0009913 | |
| GeneOntologyBiologicalProcess | epidermis development | 2.10e-06 | 461 | 28 | 7 | GO:0008544 | |
| GeneOntologyBiologicalProcess | supramolecular fiber organization | 2.98e-06 | 957 | 28 | 9 | GO:0097435 | |
| GeneOntologyBiologicalProcess | alternative mRNA splicing, via spliceosome | 3.81e-06 | 79 | 28 | 4 | GO:0000380 | |
| GeneOntologyBiologicalProcess | regulation of RNA splicing | 7.90e-06 | 207 | 28 | 5 | GO:0043484 | |
| GeneOntologyBiologicalProcess | RNA localization | 9.93e-06 | 217 | 28 | 5 | GO:0006403 | |
| GeneOntologyBiologicalProcess | regulation of mRNA metabolic process | 2.39e-05 | 443 | 28 | 6 | GO:1903311 | |
| GeneOntologyBiologicalProcess | mRNA transport | 4.21e-05 | 145 | 28 | 4 | GO:0051028 | |
| GeneOntologyBiologicalProcess | RNA transport | 8.74e-05 | 175 | 28 | 4 | GO:0050658 | |
| GeneOntologyBiologicalProcess | nucleic acid transport | 8.74e-05 | 175 | 28 | 4 | GO:0050657 | |
| GeneOntologyBiologicalProcess | establishment of RNA localization | 9.34e-05 | 178 | 28 | 4 | GO:0051236 | |
| GeneOntologyBiologicalProcess | epithelial cell differentiation | 1.26e-04 | 870 | 28 | 7 | GO:0030855 | |
| GeneOntologyBiologicalProcess | mRNA stabilization | 1.53e-04 | 77 | 28 | 3 | GO:0048255 | |
| GeneOntologyBiologicalProcess | cellular response to potassium ion | 1.60e-04 | 14 | 28 | 2 | GO:0035865 | |
| GeneOntologyBiologicalProcess | regulation of action potential | 1.78e-04 | 81 | 28 | 3 | GO:0098900 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA catabolic process | 2.20e-04 | 87 | 28 | 3 | GO:1902373 | |
| GeneOntologyBiologicalProcess | RNA stabilization | 2.28e-04 | 88 | 28 | 3 | GO:0043489 | |
| GeneOntologyBiologicalProcess | positive regulation of action potential | 2.68e-04 | 18 | 28 | 2 | GO:0045760 | |
| GeneOntologyBiologicalProcess | nucleobase-containing compound transport | 3.38e-04 | 249 | 28 | 4 | GO:0015931 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA catabolic process | 3.42e-04 | 101 | 28 | 3 | GO:1902369 | |
| GeneOntologyBiologicalProcess | response to potassium ion | 3.67e-04 | 21 | 28 | 2 | GO:0035864 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA metabolic process | 5.00e-04 | 115 | 28 | 3 | GO:1903312 | |
| GeneOntologyBiologicalProcess | positive regulation of gene expression | 5.00e-04 | 1446 | 28 | 8 | GO:0010628 | |
| GeneOntologyBiologicalProcess | peptide cross-linking | 6.11e-04 | 27 | 28 | 2 | GO:0018149 | |
| GeneOntologyBiologicalProcess | regulation of mRNA stability | 6.16e-04 | 292 | 28 | 4 | GO:0043488 | |
| GeneOntologyBiologicalProcess | regulation of mRNA splicing, via spliceosome | 6.98e-04 | 129 | 28 | 3 | GO:0048024 | |
| GeneOntologyBiologicalProcess | regulation of RNA stability | 7.52e-04 | 308 | 28 | 4 | GO:0043487 | |
| GeneOntologyBiologicalProcess | regulation of mRNA catabolic process | 7.62e-04 | 309 | 28 | 4 | GO:0061013 | |
| GeneOntologyBiologicalProcess | rRNA modification | 1.09e-03 | 36 | 28 | 2 | GO:0000154 | |
| GeneOntologyBiologicalProcess | regulation of mRNA processing | 1.26e-03 | 158 | 28 | 3 | GO:0050684 | |
| GeneOntologyBiologicalProcess | mRNA catabolic process | 1.53e-03 | 373 | 28 | 4 | GO:0006402 | |
| GeneOntologyBiologicalProcess | nuclear transport | 1.60e-03 | 378 | 28 | 4 | GO:0051169 | |
| GeneOntologyBiologicalProcess | nucleocytoplasmic transport | 1.60e-03 | 378 | 28 | 4 | GO:0006913 | |
| GeneOntologyBiologicalProcess | amyloid fibril formation | 1.70e-03 | 45 | 28 | 2 | GO:1990000 | |
| GeneOntologyBiologicalProcess | regulation of ubiquitin-protein transferase activity | 1.93e-03 | 48 | 28 | 2 | GO:0051438 | |
| GeneOntologyBiologicalProcess | import into nucleus | 2.50e-03 | 201 | 28 | 3 | GO:0051170 | |
| GeneOntologyBiologicalProcess | action potential | 2.50e-03 | 201 | 28 | 3 | GO:0001508 | |
| GeneOntologyBiologicalProcess | RNA catabolic process | 2.61e-03 | 432 | 28 | 4 | GO:0006401 | |
| GeneOntologyBiologicalProcess | epithelium development | 2.87e-03 | 1469 | 28 | 7 | GO:0060429 | |
| GeneOntologyBiologicalProcess | regulation of alternative mRNA splicing, via spliceosome | 2.90e-03 | 59 | 28 | 2 | GO:0000381 | |
| GeneOntologyBiologicalProcess | cellular response to metal ion | 3.18e-03 | 219 | 28 | 3 | GO:0071248 | |
| GeneOntologyBiologicalProcess | nucleic acid catabolic process | 3.37e-03 | 464 | 28 | 4 | GO:0141188 | |
| GeneOntologyBiologicalProcess | rRNA processing | 3.65e-03 | 230 | 28 | 3 | GO:0006364 | |
| GeneOntologyBiologicalProcess | methylation | 3.83e-03 | 234 | 28 | 3 | GO:0032259 | |
| GeneOntologyCellularComponent | keratin filament | 4.06e-11 | 97 | 28 | 7 | GO:0045095 | |
| GeneOntologyCellularComponent | intermediate filament | 1.58e-08 | 227 | 28 | 7 | GO:0005882 | |
| GeneOntologyCellularComponent | cornified envelope | 3.13e-08 | 69 | 28 | 5 | GO:0001533 | |
| GeneOntologyCellularComponent | intermediate filament cytoskeleton | 4.35e-08 | 263 | 28 | 7 | GO:0045111 | |
| GeneOntologyCellularComponent | dense fibrillar component | 7.51e-08 | 7 | 28 | 3 | GO:0001651 | |
| GeneOntologyCellularComponent | ribonucleoprotein complex | NCL HNRNPA1L2 HNRNPUL1 FMR1 GAR1 HNRNPA1 HNRNPA1L3 FBL RPS2 HNRNPH3 HNRNPA3 | 1.76e-07 | 1194 | 28 | 11 | GO:1990904 |
| GeneOntologyCellularComponent | spliceosomal complex | 3.44e-07 | 215 | 28 | 6 | GO:0005681 | |
| GeneOntologyCellularComponent | catalytic step 2 spliceosome | 8.19e-06 | 97 | 28 | 4 | GO:0071013 | |
| GeneOntologyCellularComponent | nucleoplasmic periphery of the nuclear pore complex | 2.59e-05 | 6 | 28 | 2 | GO:1990826 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 3.57e-05 | 287 | 28 | 5 | GO:0035770 | |
| GeneOntologyCellularComponent | polymeric cytoskeletal fiber | 1.42e-04 | 899 | 28 | 7 | GO:0099513 | |
| GeneOntologyCellularComponent | Cajal body | 1.91e-04 | 84 | 28 | 3 | GO:0015030 | |
| GeneOntologyCellularComponent | dendritic spine head | 2.05e-04 | 16 | 28 | 2 | GO:0044327 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | 3.29e-04 | 1377 | 28 | 8 | GO:0140513 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 4.30e-04 | 269 | 28 | 4 | GO:0036464 | |
| GeneOntologyCellularComponent | supramolecular fiber | 7.41e-04 | 1179 | 28 | 7 | GO:0099512 | |
| GeneOntologyCellularComponent | supramolecular polymer | 7.72e-04 | 1187 | 28 | 7 | GO:0099081 | |
| GeneOntologyCellularComponent | sno(s)RNA-containing ribonucleoprotein complex | 8.37e-04 | 32 | 28 | 2 | GO:0005732 | |
| GeneOntologyCellularComponent | fibrillar center | 1.16e-03 | 156 | 28 | 3 | GO:0001650 | |
| GeneOntologyCellularComponent | postsynaptic cytosol | 1.65e-03 | 45 | 28 | 2 | GO:0099524 | |
| GeneOntologyCellularComponent | presynaptic cytosol | 1.96e-03 | 49 | 28 | 2 | GO:0099523 | |
| GeneOntologyCellularComponent | perikaryon | 3.22e-03 | 223 | 28 | 3 | GO:0043204 | |
| GeneOntologyCellularComponent | cytosolic region | 3.95e-03 | 70 | 28 | 2 | GO:0099522 | |
| GeneOntologyCellularComponent | nuclear body | 6.39e-03 | 903 | 28 | 5 | GO:0016604 | |
| GeneOntologyCellularComponent | cytoplasmic stress granule | 7.30e-03 | 96 | 28 | 2 | GO:0010494 | |
| HumanPheno | Dyscalculia | 2.64e-07 | 24 | 13 | 4 | HP:0002442 | |
| HumanPheno | Progressive distal muscular atrophy | 1.79e-06 | 38 | 13 | 4 | HP:0008955 | |
| HumanPheno | Jaw hyperreflexia | 2.45e-06 | 41 | 13 | 4 | HP:0033683 | |
| HumanPheno | Fatigable weakness of swallowing muscles | 2.71e-06 | 42 | 13 | 4 | HP:0030195 | |
| HumanPheno | Laryngospasm | 2.71e-06 | 42 | 13 | 4 | HP:0025425 | |
| HumanPheno | Hoffmann sign | 3.92e-06 | 46 | 13 | 4 | HP:0031993 | |
| HumanPheno | Abnormal larynx physiology | 4.66e-06 | 48 | 13 | 4 | HP:0025424 | |
| HumanPheno | Amyotrophic lateral sclerosis | 5.07e-06 | 49 | 13 | 4 | HP:0007354 | |
| HumanPheno | Tongue atrophy | 6.45e-06 | 52 | 13 | 4 | HP:0012473 | |
| HumanPheno | Frontotemporal dementia | 6.45e-06 | 52 | 13 | 4 | HP:0002145 | |
| HumanPheno | Xerostomia | 8.09e-06 | 55 | 13 | 4 | HP:0000217 | |
| HumanPheno | Dementia | 9.19e-06 | 225 | 13 | 6 | HP:0000726 | |
| HumanPheno | Abnormality of cognition | 9.19e-06 | 225 | 13 | 6 | HP:0002302 | |
| HumanPheno | Fatigable weakness of respiratory muscles | 1.00e-05 | 58 | 13 | 4 | HP:0030196 | |
| HumanPheno | Fatigable weakness of bulbar muscles | 1.23e-05 | 61 | 13 | 4 | HP:0030192 | |
| HumanPheno | Motor neuron atrophy | 1.68e-05 | 66 | 13 | 4 | HP:0007373 | |
| HumanPheno | Tongue fasciculations | 2.66e-05 | 74 | 13 | 4 | HP:0001308 | |
| HumanPheno | Dysphonia | 2.92e-05 | 159 | 13 | 5 | HP:0001618 | |
| HumanPheno | Mood alterations | 3.40e-05 | 164 | 13 | 5 | HP:0001296 | |
| HumanPheno | Emotional lability | 3.40e-05 | 164 | 13 | 5 | HP:0000712 | |
| HumanPheno | Congenital bullous ichthyosiform erythroderma | 3.60e-05 | 4 | 13 | 2 | HP:0007475 | |
| HumanPheno | Depression | 4.17e-05 | 448 | 13 | 7 | HP:0000716 | |
| HumanPheno | Neurodegeneration | 4.82e-05 | 86 | 13 | 4 | HP:0002180 | |
| HumanPheno | Steppage gait | 6.85e-05 | 94 | 13 | 4 | HP:0003376 | |
| HumanPheno | Muscle fibrillation | 7.75e-05 | 97 | 13 | 4 | HP:0010546 | |
| HumanPheno | Spastic paraparesis | 8.06e-05 | 98 | 13 | 4 | HP:0002313 | |
| HumanPheno | Cachexia | 8.73e-05 | 100 | 13 | 4 | HP:0004326 | |
| HumanPheno | Orthopnea | 1.18e-04 | 108 | 13 | 4 | HP:0012764 | |
| HumanPheno | Abnormal fear-induced behavior | 1.37e-04 | 538 | 13 | 7 | HP:0100852 | |
| HumanPheno | Paraparesis | 1.46e-04 | 114 | 13 | 4 | HP:0002385 | |
| HumanPheno | Abnormality of the voice | 1.49e-04 | 545 | 13 | 7 | HP:0001608 | |
| HumanPheno | Abnormal tongue physiology | 1.51e-04 | 115 | 13 | 4 | HP:0030810 | |
| HumanPheno | Abnormal blistering of the skin | 1.51e-04 | 115 | 13 | 4 | HP:0008066 | |
| HumanPheno | Knuckle pad | 1.67e-04 | 8 | 13 | 2 | HP:0032541 | |
| HumanPheno | Neuronal loss in the cerebral cortex | 1.67e-04 | 8 | 13 | 2 | HP:0007190 | |
| HumanPheno | Distal amyotrophy | 1.72e-04 | 230 | 13 | 5 | HP:0003693 | |
| HumanPheno | Fatigable weakness | 1.83e-04 | 121 | 13 | 4 | HP:0003473 | |
| HumanPheno | Abnormal synaptic transmission at the neuromuscular junction | 1.89e-04 | 122 | 13 | 4 | HP:0003398 | |
| HumanPheno | Abnormal peripheral nervous system synaptic transmission | 1.89e-04 | 122 | 13 | 4 | HP:0030191 | |
| HumanPheno | Abnormal synaptic transmission | 1.89e-04 | 122 | 13 | 4 | HP:0012535 | |
| HumanPheno | Psychomotor regression | 2.09e-04 | 390 | 13 | 6 | HP:0002489 | |
| HumanPheno | Mental deterioration | 2.09e-04 | 390 | 13 | 6 | HP:0001268 | |
| HumanPheno | Retrocollis | 2.14e-04 | 9 | 13 | 2 | HP:0002544 | |
| HumanPheno | Palmoplantar hyperkeratosis | 2.35e-04 | 129 | 13 | 4 | HP:0000972 | |
| HumanPheno | Palmar hyperkeratosis | 2.49e-04 | 131 | 13 | 4 | HP:0010765 | |
| HumanPheno | Plantar hyperkeratosis | 2.57e-04 | 132 | 13 | 4 | HP:0007556 | |
| HumanPheno | Generalized muscle weakness | 2.72e-04 | 134 | 13 | 4 | HP:0003324 | |
| HumanPheno | Fasciculations | 2.88e-04 | 136 | 13 | 4 | HP:0002380 | |
| HumanPheno | Dysarthria | 3.09e-04 | 611 | 13 | 7 | HP:0001260 | |
| HumanPheno | Epidermal hyperkeratosis | 3.26e-04 | 11 | 13 | 2 | HP:0007543 | |
| HumanPheno | Palmoplantar blistering | 3.26e-04 | 11 | 13 | 2 | HP:0007446 | |
| HumanPheno | Diffuse palmoplantar hyperkeratosis | 3.26e-04 | 11 | 13 | 2 | HP:0007447 | |
| HumanPheno | Mutism | 3.33e-04 | 56 | 13 | 3 | HP:0002300 | |
| HumanPheno | Foot dorsiflexor weakness | 3.59e-04 | 144 | 13 | 4 | HP:0009027 | |
| HumanPheno | Upper limb muscle weakness | 4.31e-04 | 151 | 13 | 4 | HP:0003484 | |
| HumanPheno | Abnormality of the foot musculature | 4.31e-04 | 151 | 13 | 4 | HP:0001436 | |
| HumanPheno | Abnormal experience of reality | 4.39e-04 | 646 | 13 | 7 | HP:5200423 | |
| HumanPheno | Hyperkeratotic papule | 4.62e-04 | 13 | 13 | 2 | HP:0045059 | |
| HumanPheno | Abnormal diminished volition | 5.22e-04 | 664 | 13 | 7 | HP:0000745 | |
| HumanPheno | Paralysis | 5.24e-04 | 159 | 13 | 4 | HP:0003470 | |
| HumanPheno | Abnormality of the larynx | 5.32e-04 | 666 | 13 | 7 | HP:0001600 | |
| HumanPheno | Arm dystonia | 5.38e-04 | 14 | 13 | 2 | HP:0031960 | |
| HumanPheno | Drooling | 5.50e-04 | 161 | 13 | 4 | HP:0002307 | |
| HumanPheno | Abnormality of the musculature of the lower limbs | 5.69e-04 | 297 | 13 | 5 | HP:0001437 | |
| HumanPheno | Excessive salivation | 6.76e-04 | 170 | 13 | 4 | HP:0003781 | |
| HumanPheno | Maladaptive fear-related cognitions | 6.77e-04 | 483 | 13 | 6 | HP:5200230 | |
| HumanPheno | Anxiety | 6.77e-04 | 483 | 13 | 6 | HP:0000739 | |
| HumanPheno | Abnormality of the plantar skin of foot | 6.91e-04 | 171 | 13 | 4 | HP:0100872 | |
| HumanPheno | Anarthria | 7.07e-04 | 16 | 13 | 2 | HP:0002425 | |
| HumanPheno | Muscle spasm | 8.05e-04 | 178 | 13 | 4 | HP:0003394 | |
| HumanPheno | Proximal muscle weakness in lower limbs | 9.50e-04 | 186 | 13 | 4 | HP:0008994 | |
| HumanPheno | Abnormal judgment | 9.66e-04 | 516 | 13 | 6 | HP:5200401 | |
| HumanPheno | Generalized amyotrophy | 1.18e-03 | 86 | 13 | 3 | HP:0003700 | |
| HumanPheno | Oromandibular dystonia | 1.23e-03 | 21 | 13 | 2 | HP:0012048 | |
| HumanPheno | Hypergranulosis | 1.35e-03 | 22 | 13 | 2 | HP:0025114 | |
| HumanPheno | Degeneration of the lateral corticospinal tracts | 1.35e-03 | 22 | 13 | 2 | HP:0002314 | |
| HumanPheno | Upper-limb joint contracture | 1.41e-03 | 362 | 13 | 5 | HP:0100360 | |
| HumanPheno | Abnormal epidermal morphology | 1.52e-03 | 94 | 13 | 3 | HP:0011124 | |
| HumanPheno | Dysphagia | 1.60e-03 | 567 | 13 | 6 | HP:0002015 | |
| HumanPheno | Abnormality of salivation | 1.63e-03 | 215 | 13 | 4 | HP:0100755 | |
| HumanPheno | Abnormal mitochondrial morphology | 1.75e-03 | 25 | 13 | 2 | HP:0008322 | |
| HumanPheno | Abnormal tongue morphology | 1.88e-03 | 386 | 13 | 5 | HP:0030809 | |
| HumanPheno | Blistering by anatomical location | 1.89e-03 | 26 | 13 | 2 | HP:0033800 | |
| HumanPheno | Abnormal lower motor neuron morphology | 1.89e-03 | 26 | 13 | 2 | HP:0002366 | |
| HumanPheno | Weight loss | 1.93e-03 | 388 | 13 | 5 | HP:0001824 | |
| HumanPheno | Abnormality on pulmonary function testing | 1.93e-03 | 225 | 13 | 4 | HP:0030878 | |
| HumanPheno | Sleep abnormality | 2.08e-03 | 596 | 13 | 6 | HP:0002360 | |
| HumanPheno | Skin erosion | 2.19e-03 | 28 | 13 | 2 | HP:0200041 | |
| HumanPheno | Hyperkeratosis | 2.20e-03 | 233 | 13 | 4 | HP:0000962 | |
| HumanPheno | Abnormality of keratinization | 2.61e-03 | 244 | 13 | 4 | HP:0001035 | |
| HumanPheno | Lower limb muscle weakness | 2.61e-03 | 244 | 13 | 4 | HP:0007340 | |
| HumanPheno | Palmoplantar keratoderma | 2.65e-03 | 114 | 13 | 3 | HP:0000982 | |
| HumanPheno | Urinary bladder sphincter dysfunction | 2.86e-03 | 32 | 13 | 2 | HP:0002839 | |
| HumanPheno | Paraplegia/paraparesis | 2.89e-03 | 251 | 13 | 4 | HP:0010551 | |
| HumanPheno | Cutaneous photosensitivity | 2.92e-03 | 118 | 13 | 3 | HP:0000992 | |
| HumanPheno | Congenital ichthyosiform erythroderma | 3.04e-03 | 33 | 13 | 2 | HP:0007431 | |
| MousePheno | hyperpigmentation | 9.19e-08 | 28 | 22 | 4 | MP:0001188 | |
| MousePheno | tongue muscle hypoplasia | 2.36e-06 | 2 | 22 | 2 | MP:0030421 | |
| MousePheno | abnormal foot pad morphology | 8.59e-06 | 26 | 22 | 3 | MP:0000574 | |
| MousePheno | hyperkeratosis | 1.08e-05 | 90 | 22 | 4 | MP:0001242 | |
| MousePheno | skeletal muscle hypoplasia | 2.36e-05 | 5 | 22 | 2 | MP:0009460 | |
| MousePheno | acanthosis | 4.01e-05 | 43 | 22 | 3 | MP:0001874 | |
| MousePheno | epidermis stratum spinosum hyperplasia | 4.60e-05 | 45 | 22 | 3 | MP:0009611 | |
| MousePheno | abnormal epidermis stratum corneum morphology | 4.87e-05 | 132 | 22 | 4 | MP:0001240 | |
| MousePheno | abnormal epidermal layer morphology | 5.30e-05 | 271 | 22 | 5 | MP:0001216 | |
| MousePheno | lethality during fetal growth through weaning, complete penetrance | 6.79e-05 | 1269 | 22 | 9 | MP:0011111 | |
| MousePheno | perinatal lethality, complete penetrance | 7.52e-05 | 712 | 22 | 7 | MP:0011089 | |
| MousePheno | abnormal DNA methylation | 7.53e-05 | 53 | 22 | 3 | MP:0008877 | |
| MousePheno | neonatal lethality, complete penetrance | 1.34e-04 | 534 | 22 | 6 | MP:0011087 | |
| MousePheno | abnormal epidermis stratum spinosum morphology | 1.39e-04 | 65 | 22 | 3 | MP:0001236 | |
| MousePheno | increased tail pigmentation | 1.55e-04 | 12 | 22 | 2 | MP:0011276 | |
| MousePheno | neonatal lethality | 1.55e-04 | 799 | 22 | 7 | MP:0002058 | |
| MousePheno | abnormal epigenetic regulation of gene expression | 1.73e-04 | 70 | 22 | 3 | MP:0012167 | |
| MousePheno | decreased grip strength | 2.00e-04 | 575 | 22 | 6 | MP:0010053 | |
| MousePheno | perinatal lethality | 2.03e-04 | 1130 | 22 | 8 | MP:0002081 | |
| MousePheno | abnormal intercostal muscle morphology | 2.45e-04 | 15 | 22 | 2 | MP:0002280 | |
| MousePheno | muscle hypoplasia | 2.45e-04 | 15 | 22 | 2 | MP:0000734 | |
| MousePheno | thick epidermis | 2.57e-04 | 80 | 22 | 3 | MP:0001219 | |
| MousePheno | decreased skeletal muscle size | 2.67e-04 | 81 | 22 | 3 | MP:0010240 | |
| MousePheno | increased foot pad pigmentation | 2.80e-04 | 16 | 22 | 2 | MP:0000575 | |
| MousePheno | abnormal tongue muscle morphology | 2.80e-04 | 16 | 22 | 2 | MP:0004136 | |
| MousePheno | increased foot pigmentation | 2.80e-04 | 16 | 22 | 2 | MP:0030051 | |
| MousePheno | abnormal autopod morphology | 2.93e-04 | 390 | 22 | 5 | MP:0000572 | |
| MousePheno | abnormal skin pigmentation | 3.29e-04 | 87 | 22 | 3 | MP:0002095 | |
| MousePheno | abnormal corneocyte morphology | 3.56e-04 | 18 | 22 | 2 | MP:0030605 | |
| MousePheno | abnormal skeletal muscle size | 4.01e-04 | 93 | 22 | 3 | MP:0009458 | |
| MousePheno | shortened PR interval | 5.86e-04 | 23 | 22 | 2 | MP:0010511 | |
| MousePheno | abnormal P wave | 6.39e-04 | 24 | 22 | 2 | MP:0004070 | |
| MousePheno | blistering | 6.39e-04 | 24 | 22 | 2 | MP:0001208 | |
| MousePheno | abnormal hippocampus neuron morphology | 7.45e-04 | 115 | 22 | 3 | MP:0009939 | |
| MousePheno | abnormal tongue morphology | 8.03e-04 | 118 | 22 | 3 | MP:0000762 | |
| MousePheno | increased keratinocyte proliferation | 8.10e-04 | 27 | 22 | 2 | MP:0009583 | |
| MousePheno | abnormal foot pigmentation | 8.72e-04 | 28 | 22 | 2 | MP:0009379 | |
| MousePheno | abnormal skin physiology | 9.63e-04 | 288 | 22 | 4 | MP:0005501 | |
| MousePheno | decreased skeletal muscle mass | 1.09e-03 | 131 | 22 | 3 | MP:0004819 | |
| MousePheno | abnormal skeletal muscle mass | 1.58e-03 | 149 | 22 | 3 | MP:0004817 | |
| MousePheno | motor neuron degeneration | 1.61e-03 | 38 | 22 | 2 | MP:0000938 | |
| MousePheno | abnormal tail pigmentation | 1.69e-03 | 39 | 22 | 2 | MP:0005174 | |
| MousePheno | abnormal keratinocyte proliferation | 1.87e-03 | 41 | 22 | 2 | MP:0009582 | |
| MousePheno | abnormal sinoatrial node conduction | 1.96e-03 | 42 | 22 | 2 | MP:0006142 | |
| MousePheno | abnormal cerebral hemisphere morphology | 2.04e-03 | 599 | 22 | 5 | MP:0008540 | |
| Domain | Keratin_2_head | 5.17e-13 | 24 | 26 | 6 | IPR032444 | |
| Domain | Keratin_2_head | 5.17e-13 | 24 | 26 | 6 | PF16208 | |
| Domain | Keratin_II | 8.83e-13 | 26 | 26 | 6 | IPR003054 | |
| Domain | Intermediate_filament_CS | 2.20e-12 | 63 | 26 | 7 | IPR018039 | |
| Domain | Filament | 5.26e-12 | 71 | 26 | 7 | SM01391 | |
| Domain | IF | 5.82e-12 | 72 | 26 | 7 | PS00226 | |
| Domain | Filament | 6.43e-12 | 73 | 26 | 7 | PF00038 | |
| Domain | IF | 8.61e-12 | 76 | 26 | 7 | IPR001664 | |
| Domain | RRM_1 | 2.72e-10 | 208 | 26 | 8 | PF00076 | |
| Domain | RRM | 3.81e-10 | 217 | 26 | 8 | SM00360 | |
| Domain | RRM_dom | 5.45e-10 | 227 | 26 | 8 | IPR000504 | |
| Domain | RRM | 6.04e-10 | 230 | 26 | 8 | PS50102 | |
| Domain | - | 9.65e-10 | 244 | 26 | 8 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 1.50e-09 | 258 | 26 | 8 | IPR012677 | |
| Domain | Keratin_I | 3.64e-09 | 44 | 26 | 5 | IPR002957 | |
| Domain | GrpE_coiled_coil | 5.22e-07 | 12 | 26 | 3 | IPR013805 | |
| Domain | HnRNPA1 | 5.59e-06 | 3 | 26 | 2 | PF11627 | |
| Domain | HnRNPA1 | 5.59e-06 | 3 | 26 | 2 | IPR021662 | |
| Domain | - | 8.33e-05 | 10 | 26 | 2 | 4.10.1060.10 | |
| Domain | zf-RanBP | 4.23e-04 | 22 | 26 | 2 | PF00641 | |
| Domain | ZnF_RBZ | 4.63e-04 | 23 | 26 | 2 | SM00547 | |
| Domain | ZF_RANBP2_2 | 4.63e-04 | 23 | 26 | 2 | PS50199 | |
| Domain | ZF_RANBP2_1 | 5.05e-04 | 24 | 26 | 2 | PS01358 | |
| Domain | HR1_rho-bd | 5.48e-04 | 25 | 26 | 2 | IPR011072 | |
| Domain | Znf_RanBP2 | 5.48e-04 | 25 | 26 | 2 | IPR001876 | |
| Pathway | REACTOME_FORMATION_OF_THE_CORNIFIED_ENVELOPE | 1.39e-09 | 129 | 24 | 7 | M27649 | |
| Pathway | REACTOME_FORMATION_OF_THE_CORNIFIED_ENVELOPE | 5.71e-09 | 87 | 24 | 6 | MM15351 | |
| Pathway | WP_MRNA_PROCESSING | 2.77e-08 | 451 | 24 | 9 | MM15946 | |
| Pathway | REACTOME_KERATINIZATION | 5.15e-08 | 217 | 24 | 7 | M27640 | |
| Pathway | REACTOME_KERATINIZATION | 1.70e-07 | 153 | 24 | 6 | MM15343 | |
| Pathway | REACTOME_METABOLISM_OF_RNA | 1.64e-05 | 724 | 24 | 8 | M16843 | |
| Pathway | REACTOME_METABOLISM_OF_RNA | 5.09e-05 | 612 | 24 | 7 | MM15547 | |
| Pathway | BIOCARTA_SARS_PATHWAY | 5.80e-05 | 7 | 24 | 2 | M5374 | |
| Pathway | REACTOME_RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL | 1.39e-04 | 60 | 24 | 3 | M27613 | |
| Pathway | REACTOME_DEVELOPMENTAL_BIOLOGY | 1.54e-04 | 502 | 24 | 6 | MM14537 | |
| Pathway | WP_MECP2_AND_ASSOCIATED_RETT_SYNDROME | 2.49e-04 | 73 | 24 | 3 | M39401 | |
| Pathway | REACTOME_MRNA_SPLICING | 3.41e-04 | 201 | 24 | 4 | MM15411 | |
| Pathway | REACTOME_RRNA_PROCESSING | 3.67e-04 | 205 | 24 | 4 | M27685 | |
| Pathway | REACTOME_FGFR2_ALTERNATIVE_SPLICING | 4.18e-04 | 18 | 24 | 2 | MM15334 | |
| Pathway | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 1.14e-03 | 277 | 24 | 4 | MM15414 | |
| Pathway | KEGG_SPLICEOSOME | 1.26e-03 | 127 | 24 | 3 | M2044 | |
| Pathway | REACTOME_SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY | 1.78e-03 | 37 | 24 | 2 | M46427 | |
| Pathway | REACTOME_DEVELOPMENTAL_BIOLOGY | 1.84e-03 | 1432 | 24 | 8 | M509 | |
| Pathway | REACTOME_DIFFERENTIATION_OF_KERATINOCYTES_IN_INTERFOLLICULAR_EPIDERMIS_IN_MAMMALIAN_SKIN | 2.08e-03 | 40 | 24 | 2 | M48231 | |
| Pathway | REACTOME_MAJOR_PATHWAY_OF_RRNA_PROCESSING_IN_THE_NUCLEOLUS_AND_CYTOSOL | 3.40e-03 | 180 | 24 | 3 | MM15324 | |
| Pathway | REACTOME_SIGNALING_BY_FGFR2 | 4.94e-03 | 62 | 24 | 2 | MM15256 | |
| Pathway | REACTOME_MRNA_SPLICING | 5.38e-03 | 212 | 24 | 3 | M14033 | |
| Pathway | PID_TELOMERASE_PATHWAY | 5.74e-03 | 67 | 24 | 2 | M105 | |
| Pubmed | KRT1 KRT2 KRT3 KRT5 DDX3Y KRT9 NCL TAF15 EPM2A HNRNPA1L2 KRT76 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 5.29e-24 | 1153 | 28 | 20 | 29845934 | |
| Pubmed | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 4.44e-22 | 421 | 28 | 15 | 34650049 | |
| Pubmed | TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 5.41e-20 | 430 | 28 | 14 | 38172120 |
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | KRT1 KRT2 KRT3 KRT5 KRT9 NCL TAF15 FUS FMR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 1.03e-19 | 605 | 28 | 15 | 28977666 |
| Pubmed | KRT1 KRT2 KRT5 KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 2.44e-19 | 346 | 28 | 13 | 25324306 | |
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | KRT1 KRT2 KRT3 TARDBP KRT5 KRT9 NCL FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 4.07e-18 | 1257 | 28 | 17 | 36526897 |
| Pubmed | KRT2 TARDBP KRT5 DDX3Y NCL FUS HNRNPUL1 HNRNPA1 HNRNPH3 HNRNPA3 | 7.38e-18 | 136 | 28 | 10 | 26979993 | |
| Pubmed | The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. | TAF15 HNRNPA1L2 FUS FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.64e-17 | 147 | 28 | 10 | 28977470 |
| Pubmed | KRT1 KRT2 TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.82e-17 | 652 | 28 | 14 | 31180492 | |
| Pubmed | DDX24 promotes metastasis by regulating RPL5 in non-small cell lung cancer. | KRT1 KRT2 KRT5 KRT9 NCL VSIG8 HNRNPUL1 HNRNPA1 FBL RPS2 KRT77 | 2.37e-17 | 238 | 28 | 11 | 35864588 |
| Pubmed | SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS FAM98B HNRNPUL1 FMR1 HNRNPA1 RPS2 KRT77 | 1.22e-16 | 558 | 28 | 13 | 27591049 |
| Pubmed | 1.91e-16 | 187 | 28 | 10 | 29777862 | ||
| Pubmed | BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression. | KRT1 KRT2 TARDBP DDX3Y KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 3.28e-16 | 1318 | 28 | 16 | 30463901 |
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | TARDBP NCL TAF15 VSIG8 FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 3.49e-16 | 807 | 28 | 14 | 22681889 |
| Pubmed | Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer. | KRT1 TARDBP KRT5 KRT9 NCL FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPA3 | 5.38e-16 | 626 | 28 | 13 | 33644029 |
| Pubmed | KRT2 TARDBP KRT5 DDX3Y NCL TAF15 HNRNPA1L2 VSIG8 FUS FAM98B HNRNPUL1 HNRNPA1 FBL HNRNPA3 | 6.47e-16 | 844 | 28 | 14 | 25963833 | |
| Pubmed | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 FAM98B HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 7.30e-16 | 641 | 28 | 13 | 36057605 | |
| Pubmed | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 2.57e-15 | 707 | 28 | 13 | 19738201 | |
| Pubmed | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS FAM98B KMT2B HNRNPA1 FBL RPS2 HNRNPA3 | 2.76e-15 | 711 | 28 | 13 | 33022573 | |
| Pubmed | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 3.54e-15 | 725 | 28 | 13 | 27025967 | |
| Pubmed | TARDBP NCL TAF15 FUS FAM98B HNRNPUL1 FMR1 HNRNPA1 RPS2 KRT77 HNRNPH3 HNRNPA3 | 5.36e-15 | 551 | 28 | 12 | 34728620 | |
| Pubmed | KRT1 KRT2 TARDBP KRT5 DDX3Y KRT9 NCL HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 1.31e-14 | 803 | 28 | 13 | 36517590 | |
| Pubmed | 1.39e-14 | 286 | 28 | 10 | 32041737 | ||
| Pubmed | 1.54e-14 | 289 | 28 | 10 | 37132043 | ||
| Pubmed | The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation. | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.60e-14 | 604 | 28 | 12 | 37616343 |
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | KRT1 KRT2 TARDBP KRT5 DDX3Y KRT9 NCL TAF15 HNRNPUL1 GAR1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 1.96e-14 | 1082 | 28 | 14 | 38697112 |
| Pubmed | 2.04e-14 | 24 | 28 | 6 | 30719818 | ||
| Pubmed | 2.04e-14 | 24 | 28 | 6 | 27507811 | ||
| Pubmed | 2.50e-14 | 57 | 28 | 7 | 31862882 | ||
| Pubmed | KRT1 KRT2 KRT3 TARDBP KRT5 NCL TAF15 HNRNPA1L2 KRT76 FUS FAM98B GAR1 HNRNPA1 KRT77 HNRNPA3 | 3.86e-14 | 1442 | 28 | 15 | 35575683 | |
| Pubmed | 5.21e-14 | 63 | 28 | 7 | 16831889 | ||
| Pubmed | 5.82e-14 | 330 | 28 | 10 | 32529326 | ||
| Pubmed | ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection. | 6.97e-14 | 336 | 28 | 10 | 31253590 | |
| Pubmed | A functional reference map of the RNF8 interactome in cancer. | 7.88e-14 | 218 | 28 | 9 | 35831895 | |
| Pubmed | 8.92e-14 | 221 | 28 | 9 | 31796584 | ||
| Pubmed | TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.13e-13 | 713 | 28 | 12 | 29802200 | |
| Pubmed | Identifying biological pathways that underlie primordial short stature using network analysis. | TARDBP KRT5 NCL TAF15 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 2.88e-13 | 1024 | 28 | 13 | 24711643 |
| Pubmed | 3.87e-13 | 260 | 28 | 9 | 36199071 | ||
| Pubmed | 4.76e-13 | 266 | 28 | 9 | 19380743 | ||
| Pubmed | Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones. | KRT1 KRT2 KRT5 KRT9 NCL FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 7.51e-13 | 1415 | 28 | 14 | 28515276 |
| Pubmed | Disruption of the lamin A and matrin-3 interaction by myopathic LMNA mutations. | 1.10e-12 | 96 | 28 | 7 | 25948554 | |
| Pubmed | KRT2 TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPA3 | 1.56e-12 | 655 | 28 | 11 | 35819319 | |
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS HNRNPUL1 HNRNPA1 FBL RPS2 | 2.27e-12 | 678 | 28 | 11 | 30209976 |
| Pubmed | 2.74e-12 | 109 | 28 | 7 | 29511296 | ||
| Pubmed | 2.83e-12 | 488 | 28 | 10 | 31324722 | ||
| Pubmed | 3.00e-12 | 491 | 28 | 10 | 22623428 | ||
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | TARDBP DDX3Y NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 HNRNPH3 HNRNPA3 | 3.44e-12 | 954 | 28 | 12 | 36373674 |
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | TARDBP NCL TAF15 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 5.24e-12 | 989 | 28 | 12 | 36424410 |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 KMT2B GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 5.49e-12 | 1294 | 28 | 13 | 30804502 |
| Pubmed | TARDBP DDX3Y NCL HNRNPA1L2 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 8.11e-12 | 1335 | 28 | 13 | 29229926 | |
| Pubmed | SPOP attenuates migration and invasion of choriocarcinoma cells by promoting DHX9 degradation. | 9.60e-12 | 130 | 28 | 7 | 32905556 | |
| Pubmed | KRT1 KRT2 AVEN TARDBP KRT5 KRT9 NCL TAF15 HNRNPUL1 HNRNPA1 RPS2 | 9.80e-12 | 777 | 28 | 11 | 35844135 | |
| Pubmed | E3 Ligase Trim21 Ubiquitylates and Stabilizes Keratin 17 to Induce STAT3 Activation in Psoriasis. | 1.26e-11 | 135 | 28 | 7 | 29859926 | |
| Pubmed | 1.49e-11 | 245 | 28 | 8 | 21182205 | ||
| Pubmed | LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression. | 1.54e-11 | 580 | 28 | 10 | 35676659 | |
| Pubmed | KRT1 KRT2 KRT5 DDX3Y NCL TAF15 HNRNPA1L2 KRT76 FAM98B FMR1 HNRNPA1 RPS2 HNRNPA3 | 1.93e-11 | 1431 | 28 | 13 | 37142655 | |
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 2.25e-11 | 258 | 28 | 8 | 37794589 | |
| Pubmed | NCL TAF15 HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 2.74e-11 | 615 | 28 | 10 | 31048545 | |
| Pubmed | 2.97e-11 | 75 | 28 | 6 | 31527668 | ||
| Pubmed | Tumor suppressor BAP1 nuclear import is governed by transportin-1. | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS FAM98B HNRNPUL1 HNRNPA1 RPS2 HNRNPA3 | 2.98e-11 | 1149 | 28 | 12 | 35446349 |
| Pubmed | 3.14e-11 | 425 | 28 | 9 | 21081503 | ||
| Pubmed | 3.49e-11 | 156 | 28 | 7 | 26170170 | ||
| Pubmed | 4.36e-11 | 441 | 28 | 9 | 31239290 | ||
| Pubmed | Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes. | 5.97e-11 | 84 | 28 | 6 | 29563501 | |
| Pubmed | The cellular EJC interactome reveals higher-order mRNP structure and an EJC-SR protein nexus. | 6.13e-11 | 169 | 28 | 7 | 23084401 | |
| Pubmed | TARDBP DDX3Y NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 7.66e-11 | 1247 | 28 | 12 | 27684187 | |
| Pubmed | TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1. | KRT1 DDX3Y NCL HNRNPA1L2 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPA3 | 8.28e-11 | 949 | 28 | 11 | 36574265 |
| Pubmed | C9orf72 protein quality control by UBR5-mediated heterotypic ubiquitin chains. | TARDBP DDX3Y NCL TAF15 HNRNPA1L2 FUS HNRNPUL1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 8.40e-11 | 1257 | 28 | 12 | 37317656 |
| Pubmed | LINKIN, a new transmembrane protein necessary for cell adhesion. | 9.23e-11 | 480 | 28 | 9 | 25437307 | |
| Pubmed | TRIM25 and DEAD-Box RNA Helicase DDX3X Cooperate to Regulate RIG-I-Mediated Antiviral Immunity. | 9.76e-11 | 91 | 28 | 6 | 34445801 | |
| Pubmed | 1.10e-10 | 11 | 28 | 4 | 33469008 | ||
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | TARDBP NCL HNRNPA1L2 HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.17e-10 | 714 | 28 | 10 | 28302793 |
| Pubmed | The P-body component USP52/PAN2 is a novel regulator of HIF1A mRNA stability. | 1.52e-10 | 328 | 28 | 8 | 23398456 | |
| Pubmed | 2.01e-10 | 340 | 28 | 8 | 24332808 | ||
| Pubmed | 2.37e-10 | 347 | 28 | 8 | 16033648 | ||
| Pubmed | SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. | 2.71e-10 | 353 | 28 | 8 | 27545878 | |
| Pubmed | 2.77e-10 | 45 | 28 | 5 | 30619335 | ||
| Pubmed | TARDBP NCL HNRNPA1L2 FUS FAM98B HNRNPUL1 HNRNPA1 KRT77 HNRNPA3 | 3.16e-10 | 552 | 28 | 9 | 36293380 | |
| Pubmed | 3.43e-10 | 216 | 28 | 7 | 37640791 | ||
| Pubmed | 3.86e-10 | 114 | 28 | 6 | 31553912 | ||
| Pubmed | 4.28e-10 | 223 | 28 | 7 | 20020773 | ||
| Pubmed | FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. | 4.42e-10 | 224 | 28 | 7 | 28443643 | |
| Pubmed | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. | 5.87e-10 | 52 | 28 | 5 | 24591637 | |
| Pubmed | 6.12e-10 | 123 | 28 | 6 | 35583604 | ||
| Pubmed | 6.14e-10 | 847 | 28 | 10 | 35850772 | ||
| Pubmed | 6.36e-10 | 236 | 28 | 7 | 36339263 | ||
| Pubmed | 6.67e-10 | 601 | 28 | 9 | 33658012 | ||
| Pubmed | 7.14e-10 | 54 | 28 | 5 | 35474131 | ||
| Pubmed | 8.02e-10 | 244 | 28 | 7 | 29884807 | ||
| Pubmed | 8.25e-10 | 245 | 28 | 7 | 35652658 | ||
| Pubmed | A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. | 1.06e-09 | 254 | 28 | 7 | 28431233 | |
| Pubmed | 1.79e-09 | 274 | 28 | 7 | 34244482 | ||
| Pubmed | 1.85e-09 | 65 | 28 | 5 | 32521226 | ||
| Pubmed | Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. | 1.87e-09 | 4 | 28 | 3 | 25062688 | |
| Pubmed | RNA-binding proteins in neurological development and disease. | 1.87e-09 | 4 | 28 | 3 | 32865115 | |
| Pubmed | New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules. | 2.25e-09 | 462 | 28 | 8 | 31138677 | |
| Pubmed | 2.28e-09 | 153 | 28 | 6 | 28225217 | ||
| Pubmed | 2.88e-09 | 159 | 28 | 6 | 22751105 | ||
| Pubmed | 2.94e-09 | 23 | 28 | 4 | 18320585 | ||
| Pubmed | 2.99e-09 | 295 | 28 | 7 | 26209609 | ||
| Interaction | HEXIM1 interactions | KRT1 KRT2 KRT3 KRT5 DDX3Y KRT9 NCL TAF15 EPM2A HNRNPA1L2 KRT76 FUS HNRNPUL1 HNRNPA1 RPS2 KRT77 HNRNPH3 HNRNPA3 | 1.75e-18 | 913 | 27 | 18 | int:HEXIM1 |
| Interaction | TRIM31 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 2.11e-18 | 454 | 27 | 15 | int:TRIM31 |
| Interaction | DCUN1D1 interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 HNRNPA1 RPS2 KRT77 HNRNPH3 HNRNPA3 | 7.24e-18 | 275 | 27 | 13 | int:DCUN1D1 |
| Interaction | LARP7 interactions | KRT1 KRT2 KRT3 KRT5 DDX3Y KRT9 NCL TAF15 HNRNPA1L2 KRT76 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPA3 | 5.84e-17 | 1113 | 27 | 18 | int:LARP7 |
| Interaction | MYCN interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 7.94e-17 | 1373 | 27 | 19 | int:MYCN |
| Interaction | MEPCE interactions | KRT1 KRT2 KRT5 DDX3Y KRT9 NCL TAF15 HNRNPA1L2 KRT76 FUS HNRNPUL1 HNRNPA1 FBL RPS2 KRT77 HNRNPA3 | 8.70e-16 | 859 | 27 | 16 | int:MEPCE |
| Interaction | CAND1 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 KRT76 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 1.63e-15 | 894 | 27 | 16 | int:CAND1 |
| Interaction | METTL14 interactions | KRT1 KRT2 TARDBP KRT5 DDX3Y KRT9 NCL FUS HNRNPUL1 HNRNPA1 FBL RPS2 KRT77 HNRNPA3 | 1.91e-15 | 558 | 27 | 14 | int:METTL14 |
| Interaction | CUL4B interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 KRT76 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 2.35e-15 | 728 | 27 | 15 | int:CUL4B |
| Interaction | CUL5 interactions | KRT1 KRT2 KRT3 KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 HNRNPA1 RPS2 KRT77 HNRNPH3 HNRNPA3 | 2.38e-15 | 567 | 27 | 14 | int:CUL5 |
| Interaction | CHD3 interactions | KRT1 KRT2 KRT3 KRT5 KRT9 NCL TAF15 FUS FMR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 4.17e-15 | 757 | 27 | 15 | int:CHD3 |
| Interaction | CUL2 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 KRT76 FUS HNRNPUL1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 4.22e-15 | 591 | 27 | 14 | int:CUL2 |
| Interaction | MECP2 interactions | KRT1 KRT2 TARDBP KRT5 DDX3Y SP3 KRT9 NCL TAF15 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 2.02e-14 | 1287 | 27 | 17 | int:MECP2 |
| Interaction | NEDD8 interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 KRT76 FUS HNRNPUL1 HNRNPA1 HNRNPH3 HNRNPA3 | 3.42e-14 | 393 | 27 | 12 | int:NEDD8 |
| Interaction | COPS5 interactions | KRT1 KRT2 KRT3 KRT5 KRT9 NCL TAF15 KRT76 FUS FAM98B HNRNPUL1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 4.24e-14 | 1102 | 27 | 16 | int:COPS5 |
| Interaction | ACE2 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 4.48e-14 | 1106 | 27 | 16 | int:ACE2 |
| Interaction | RBM45 interactions | KRT2 TARDBP KRT5 DDX3Y NCL FUS HNRNPUL1 HNRNPA1 HNRNPH3 HNRNPA3 | 7.61e-14 | 207 | 27 | 10 | int:RBM45 |
| Interaction | CHD4 interactions | KRT1 KRT2 KRT3 KRT5 KRT9 NCL TAF15 FUS FMR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 9.61e-14 | 938 | 27 | 15 | int:CHD4 |
| Interaction | UFL1 interactions | KRT1 KRT2 TARDBP KRT9 NCL FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 3.80e-13 | 1031 | 27 | 15 | int:UFL1 |
| Interaction | DDX3X interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 RPS2 KRT77 | 4.90e-13 | 651 | 27 | 13 | int:DDX3X |
| Interaction | WDR77 interactions | NCL TAF15 HNRNPA1L2 FUS FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 5.28e-13 | 361 | 27 | 11 | int:WDR77 |
| Interaction | PRMT8 interactions | 7.83e-13 | 104 | 27 | 8 | int:PRMT8 | |
| Interaction | NR2C2 interactions | KRT1 KRT2 TARDBP DDX3Y KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.75e-12 | 1403 | 27 | 16 | int:NR2C2 |
| Interaction | COPS6 interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 KRT76 FUS HNRNPUL1 RPS2 HNRNPH3 | 2.00e-12 | 408 | 27 | 11 | int:COPS6 |
| Interaction | PRMT1 interactions | TARDBP NCL TAF15 FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 KRT77 HNRNPH3 HNRNPA3 | 2.04e-12 | 929 | 27 | 14 | int:PRMT1 |
| Interaction | HNRNPA1 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 HNRNPA1 HNRNPH3 HNRNPA3 | 2.56e-12 | 945 | 27 | 14 | int:HNRNPA1 |
| Interaction | ARIH2 interactions | 4.88e-12 | 314 | 27 | 10 | int:ARIH2 | |
| Interaction | KRT25 interactions | 5.04e-12 | 35 | 27 | 6 | int:KRT25 | |
| Interaction | RNF208 interactions | 6.21e-12 | 75 | 27 | 7 | int:RNF208 | |
| Interaction | BTF3 interactions | KRT1 TARDBP KRT5 KRT9 NCL FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPA3 | 6.51e-12 | 799 | 27 | 13 | int:BTF3 |
| Interaction | MIDN interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 8.25e-12 | 626 | 27 | 12 | int:MIDN |
| Interaction | VCAM1 interactions | KRT1 KRT2 TARDBP KRT9 NCL FUS HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.03e-11 | 475 | 27 | 11 | int:VCAM1 |
| Interaction | KIF20A interactions | TARDBP NCL TAF15 HNRNPA1L2 VSIG8 FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.09e-11 | 1052 | 27 | 14 | int:KIF20A |
| Interaction | MIR106A interactions | 1.29e-11 | 83 | 27 | 7 | int:MIR106A | |
| Interaction | CUL7 interactions | TARDBP KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.31e-11 | 845 | 27 | 13 | int:CUL7 |
| Interaction | FBP1 interactions | 1.35e-11 | 348 | 27 | 10 | int:FBP1 | |
| Interaction | FN1 interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.37e-11 | 848 | 27 | 13 | int:FN1 |
| Interaction | MIR18B interactions | 1.53e-11 | 85 | 27 | 7 | int:MIR18B | |
| Interaction | MCM2 interactions | KRT2 TARDBP KRT5 DDX3Y NCL TAF15 HNRNPA1L2 VSIG8 FUS FAM98B HNRNPUL1 HNRNPA1 FBL HNRNPA3 | 1.56e-11 | 1081 | 27 | 14 | int:MCM2 |
| Interaction | RC3H2 interactions | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 | 1.73e-11 | 667 | 27 | 12 | int:RC3H2 |
| Interaction | EIF4A3 interactions | KRT1 KRT2 KRT5 KRT9 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPA3 | 1.75e-11 | 499 | 27 | 11 | int:EIF4A3 |
| Interaction | CYLD interactions | KRT1 KRT2 TARDBP KRT5 KRT9 NCL FUS FAM98B HNRNPUL1 FMR1 HNRNPA1 RPS2 KRT77 | 1.84e-11 | 868 | 27 | 13 | int:CYLD |
| Interaction | NMRAL1 interactions | 1.87e-11 | 244 | 27 | 9 | int:NMRAL1 | |
| Interaction | RC3H1 interactions | KRT1 KRT2 KRT5 KRT9 NCL FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPA3 | 2.05e-11 | 677 | 27 | 12 | int:RC3H1 |
| Interaction | KRT17 interactions | 2.50e-11 | 252 | 27 | 9 | int:KRT17 | |
| Interaction | ARAF interactions | 2.89e-11 | 376 | 27 | 10 | int:ARAF | |
| Interaction | MIRLET7F1 interactions | 3.15e-11 | 94 | 27 | 7 | int:MIRLET7F1 | |
| Interaction | RPS6KB2 interactions | 3.41e-11 | 261 | 27 | 9 | int:RPS6KB2 | |
| Interaction | RLIM interactions | 4.35e-11 | 392 | 27 | 10 | int:RLIM | |
| Interaction | RIOK1 interactions | KRT1 DDX3Y NCL FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 6.26e-11 | 562 | 27 | 11 | int:RIOK1 |
| Interaction | MIR34A interactions | 6.48e-11 | 104 | 27 | 7 | int:MIR34A | |
| Interaction | PRC1 interactions | TARDBP NCL TAF15 HNRNPA1L2 FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 7.64e-11 | 973 | 27 | 13 | int:PRC1 |
| Interaction | RNF8 interactions | 8.74e-11 | 421 | 27 | 10 | int:RNF8 | |
| Interaction | DDRGK1 interactions | KRT1 KRT2 TARDBP KRT9 NCL FUS FAM98B HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPA3 | 1.07e-10 | 1249 | 27 | 14 | int:DDRGK1 |
| Interaction | KRT14 interactions | 1.11e-10 | 192 | 27 | 8 | int:KRT14 | |
| Interaction | DDX24 interactions | KRT1 KRT2 KRT5 KRT9 NCL VSIG8 HNRNPUL1 HNRNPA1 FBL RPS2 KRT77 | 1.17e-10 | 596 | 27 | 11 | int:DDX24 |
| Interaction | MIRLET7G interactions | 1.50e-10 | 117 | 27 | 7 | int:MIRLET7G | |
| Interaction | HNRNPU interactions | KRT3 AVEN TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.64e-10 | 1035 | 27 | 13 | int:HNRNPU |
| Interaction | NDN interactions | 1.79e-10 | 453 | 27 | 10 | int:NDN | |
| Interaction | MATR3 interactions | TARDBP TAF15 HNRNPA1L2 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 3.19e-10 | 655 | 27 | 11 | int:MATR3 |
| Interaction | MIR138-1 interactions | 3.30e-10 | 68 | 27 | 6 | int:MIR138-1 | |
| Interaction | WDR5 interactions | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS FAM98B KMT2B HNRNPA1 FBL RPS2 HNRNPA3 | 3.53e-10 | 1101 | 27 | 13 | int:WDR5 |
| Interaction | CUL1 interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 FUS HNRNPUL1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 4.02e-10 | 876 | 27 | 12 | int:CUL1 |
| Interaction | KRT28 interactions | 4.06e-10 | 30 | 27 | 5 | int:KRT28 | |
| Interaction | PCBP1 interactions | TARDBP DDX3Y NCL TAF15 FUS FMR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 4.12e-10 | 671 | 27 | 11 | int:PCBP1 |
| Interaction | PHB1 interactions | KRT1 KRT2 TARDBP KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 HNRNPA1 RPS2 HNRNPH3 HNRNPA3 | 4.50e-10 | 1123 | 27 | 13 | int:PHB1 |
| Interaction | MIR20A interactions | 5.55e-10 | 74 | 27 | 6 | int:MIR20A | |
| Interaction | KRT36 interactions | 5.55e-10 | 74 | 27 | 6 | int:KRT36 | |
| Interaction | RNF113A interactions | KRT2 TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL RPS2 HNRNPA3 | 5.71e-10 | 692 | 27 | 11 | int:RNF113A |
| Interaction | MIR7-3 interactions | 6.54e-10 | 76 | 27 | 6 | int:MIR7-3 | |
| Interaction | MIR16-1 interactions | 6.54e-10 | 76 | 27 | 6 | int:MIR16-1 | |
| Interaction | MIR199A2 interactions | 6.54e-10 | 76 | 27 | 6 | int:MIR199A2 | |
| Interaction | EFTUD2 interactions | KRT1 KRT2 KRT5 KRT9 NCL TAF15 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPA3 | 7.64e-10 | 1449 | 27 | 14 | int:EFTUD2 |
| Interaction | MIR98 interactions | 7.67e-10 | 78 | 27 | 6 | int:MIR98 | |
| Interaction | MIR222 interactions | 8.29e-10 | 79 | 27 | 6 | int:MIR222 | |
| Interaction | MIR143 interactions | 8.95e-10 | 80 | 27 | 6 | int:MIR143 | |
| Interaction | PIH1D1 interactions | KRT1 KRT2 KRT5 KRT9 NCL FUS HNRNPUL1 HNRNPA1 FBL RPS2 HNRNPA3 | 1.02e-09 | 731 | 27 | 11 | int:PIH1D1 |
| Interaction | MIR10B interactions | 1.04e-09 | 82 | 27 | 6 | int:MIR10B | |
| Interaction | ITGA4 interactions | 1.11e-09 | 547 | 27 | 10 | int:ITGA4 | |
| Interaction | MIR31 interactions | 1.21e-09 | 84 | 27 | 6 | int:MIR31 | |
| Interaction | MIR7-2 interactions | 1.21e-09 | 84 | 27 | 6 | int:MIR7-2 | |
| Interaction | MIR200B interactions | 1.21e-09 | 84 | 27 | 6 | int:MIR200B | |
| Interaction | DES interactions | 1.24e-09 | 158 | 27 | 7 | int:DES | |
| Interaction | MIR107 interactions | 1.30e-09 | 85 | 27 | 6 | int:MIR107 | |
| Interaction | MIR9-1 interactions | 1.30e-09 | 85 | 27 | 6 | int:MIR9-1 | |
| Interaction | MAGOH interactions | 1.40e-09 | 264 | 27 | 8 | int:MAGOH | |
| Interaction | SNRNP70 interactions | TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.51e-09 | 984 | 27 | 12 | int:SNRNP70 |
| Interaction | DDX5 interactions | TARDBP NCL TAF15 FUS HNRNPUL1 FMR1 HNRNPA1 FBL HNRNPH3 HNRNPA3 | 1.60e-09 | 568 | 27 | 10 | int:DDX5 |
| Interaction | MIR141 interactions | 1.60e-09 | 88 | 27 | 6 | int:MIR141 | |
| Interaction | DDX39B interactions | 1.66e-09 | 570 | 27 | 10 | int:DDX39B | |
| Interaction | BRCA1 interactions | AVEN TARDBP NCL TAF15 VSIG8 FUS HNRNPUL1 GAR1 HNRNPA1 FBL RPS2 HNRNPH3 HNRNPA3 | 1.66e-09 | 1249 | 27 | 13 | int:BRCA1 |
| Interaction | SMC5 interactions | TARDBP DDX3Y NCL TAF15 HNRNPA1L2 FUS FAM98B HNRNPUL1 GAR1 HNRNPA1 HNRNPH3 HNRNPA3 | 1.82e-09 | 1000 | 27 | 12 | int:SMC5 |
| Interaction | MIR200C interactions | 1.97e-09 | 91 | 27 | 6 | int:MIR200C | |
| Interaction | MIR205 interactions | 2.24e-09 | 93 | 27 | 6 | int:MIR205 | |
| Interaction | KRT33B interactions | 2.24e-09 | 93 | 27 | 6 | int:KRT33B | |
| Interaction | MIR19B2 interactions | 2.40e-09 | 94 | 27 | 6 | int:MIR19B2 | |
| Interaction | DDX17 interactions | 2.59e-09 | 426 | 27 | 9 | int:DDX17 | |
| Interaction | METTL3 interactions | 2.69e-09 | 287 | 27 | 8 | int:METTL3 | |
| Interaction | MIRLET7A2 interactions | 2.72e-09 | 96 | 27 | 6 | int:MIRLET7A2 | |
| Interaction | KRT15 interactions | 2.85e-09 | 178 | 27 | 7 | int:KRT15 | |
| Cytoband | 12q13.13 | 2.82e-12 | 67 | 28 | 6 | 12q13.13 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12q13 | 5.38e-09 | 423 | 28 | 7 | chr12q13 | |
| Cytoband | 19q13.1 | 5.22e-04 | 55 | 28 | 2 | 19q13.1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr15q14 | 6.42e-04 | 61 | 28 | 2 | chr15q14 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q31 | 5.29e-03 | 178 | 28 | 2 | chr2q31 | |
| GeneFamily | Keratins, type II | 4.48e-13 | 27 | 22 | 6 | 609 | |
| GeneFamily | RNA binding motif containing | 9.03e-11 | 213 | 22 | 8 | 725 | |
| GeneFamily | Zinc fingers RANBP2-type |RNA binding motif containing | 2.93e-04 | 21 | 22 | 2 | 89 | |
| Coexpression | BUSSLINGER_ESOPHAGEAL_PROLIFERATING_BASAL_CELLS | 9.10e-07 | 70 | 28 | 4 | M40002 | |
| Coexpression | BUSSLINGER_ESOPHAGEAL_EARLY_SUPRABASAL_CELLS | 1.48e-06 | 79 | 28 | 4 | M40003 | |
| Coexpression | HALLMARK_MYC_TARGETS_V1 | 2.10e-06 | 200 | 28 | 5 | M5926 | |
| Coexpression | FAN_OVARY_CL1_GPRC5A_TNFRS12A_HIGH_SELECTABLE_FOLLICLE_STROMAL_CELL | 2.57e-06 | 380 | 28 | 6 | M41703 | |
| Coexpression | CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN | 5.08e-06 | 669 | 28 | 7 | M18635 | |
| Coexpression | ZHANG_UTERUS_C7_EPITHELIAL2_CELL | 1.61e-05 | 799 | 28 | 7 | MM16613 | |
| Coexpression | GAUTAM_EYE_CORNEA_FIBROBLASTS | 2.76e-05 | 165 | 28 | 4 | M43617 | |
| Coexpression | LIU_CDX2_TARGETS_DN | 3.07e-05 | 8 | 28 | 2 | M19218 | |
| Coexpression | TRAVAGLINI_LUNG_PROLIFERATING_BASAL_CELL | 3.25e-05 | 891 | 28 | 7 | M41654 | |
| Coexpression | TRAVAGLINI_LUNG_PROXIMAL_BASAL_CELL | 4.48e-05 | 629 | 28 | 6 | M41652 | |
| Coexpression | BUSSLINGER_DUODENAL_TRANSIT_AMPLIFYING_CELLS | 5.18e-05 | 194 | 28 | 4 | M40026 | |
| Coexpression | GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN | 5.39e-05 | 196 | 28 | 4 | M10002 | |
| Coexpression | HSIAO_HOUSEKEEPING_GENES | 5.73e-05 | 397 | 28 | 5 | M11197 | |
| Coexpression | PAL_PRMT5_TARGETS_UP | 7.05e-05 | 210 | 28 | 4 | MM1172 | |
| Coexpression | JIANG_MELANOMA_TRM8_CD4 | 8.00e-05 | 426 | 28 | 5 | M48972 | |
| Coexpression | HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN | 2.49e-04 | 115 | 28 | 3 | M19849 | |
| Coexpression | MUELLER_PLURINET | 2.74e-04 | 299 | 28 | 4 | M123 | |
| Coexpression | ZHANG_UTERUS_C1_REGENERATIVE_UP | 2.84e-04 | 302 | 28 | 4 | MM16604 | |
| Coexpression | HAY_BONE_MARROW_PRO_B | 2.92e-04 | 304 | 28 | 4 | M39208 | |
| Coexpression | BUSSLINGER_DUODENAL_DIFFERENTIATING_STEM_CELLS | 2.95e-04 | 305 | 28 | 4 | M40025 | |
| Coexpression | COLLER_MYC_TARGETS_UP | 2.99e-04 | 24 | 28 | 2 | M5955 | |
| Coexpression | BUSSLINGER_DUODENAL_STEM_CELLS | 3.18e-04 | 311 | 28 | 4 | M40024 | |
| Coexpression | LUI_THYROID_CANCER_CLUSTER_3 | 4.09e-04 | 28 | 28 | 2 | M4290 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_C_D_UP | 4.71e-04 | 143 | 28 | 3 | M16927 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_C_D_UP | 4.71e-04 | 143 | 28 | 3 | MM788 | |
| Coexpression | PUJANA_ATM_PCC_NETWORK | 5.23e-04 | 1394 | 28 | 7 | M9585 | |
| Coexpression | GSE12507_PDC_CELL_LINE_VS_IMMATUE_T_CELL_LINE_UP | 5.74e-04 | 153 | 28 | 3 | M438 | |
| Coexpression | LUI_TARGETS_OF_PAX8_PPARG_FUSION | 6.04e-04 | 34 | 28 | 2 | M13314 | |
| Coexpression | GSE6269_FLU_VS_E_COLI_INF_PBMC_DN | 6.78e-04 | 162 | 28 | 3 | M5654 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | 7.85e-04 | 1492 | 28 | 7 | M40023 | |
| Coexpression | GSE3565_CTRL_VS_LPS_INJECTED_SPLENOCYTES_DN | 8.48e-04 | 175 | 28 | 3 | M6328 | |
| Coexpression | BENPORATH_SOX2_TARGETS | 9.78e-04 | 734 | 28 | 5 | M3835 | |
| Coexpression | TABULA_MURIS_SENIS_LARGE_INTESTINE_SECRETORY_CELL_AGEING | 9.78e-04 | 734 | 28 | 5 | MM3740 | |
| Coexpression | GSE5099_DAY3_VS_DAY7_MCSF_TREATED_MACROPHAGE_DN | 9.80e-04 | 184 | 28 | 3 | M6593 | |
| Coexpression | TRAVAGLINI_LUNG_BASAL_CELL | 1.04e-03 | 188 | 28 | 3 | M41651 | |
| Coexpression | ONO_FOXP3_TARGETS_DN | 1.06e-03 | 45 | 28 | 2 | MM1271 | |
| Coexpression | SHEN_SMARCA2_TARGETS_UP | 1.06e-03 | 429 | 28 | 4 | M29 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN | 1.09e-03 | 432 | 28 | 4 | M41149 | |
| Coexpression | LUI_THYROID_CANCER_PAX8_PPARG_DN | 1.11e-03 | 46 | 28 | 2 | M4902 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_PROERYTHROBLAST_AGEING | 1.12e-03 | 1144 | 28 | 6 | MM3843 | |
| Coexpression | PUJANA_CHEK2_PCC_NETWORK | 1.15e-03 | 761 | 28 | 5 | M11961 | |
| Coexpression | GSE360_CTRL_VS_B_MALAYI_HIGH_DOSE_DC_UP | 1.19e-03 | 197 | 28 | 3 | M5150 | |
| Coexpression | GSE16450_CTRL_VS_IFNA_12H_STIM_IMMATURE_NEURON_CELL_LINE_UP | 1.19e-03 | 197 | 28 | 3 | M7403 | |
| Coexpression | HOUNKPE_HOUSEKEEPING_GENES | 1.20e-03 | 1158 | 28 | 6 | MM1338 | |
| Coexpression | SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN | 1.20e-03 | 48 | 28 | 2 | M2138 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_T_CELL_AGEING | 1.22e-03 | 445 | 28 | 4 | MM3853 | |
| Coexpression | GSE17721_CTRL_VS_PAM3CSK4_4H_BMDC_DN | 1.23e-03 | 199 | 28 | 3 | M3738 | |
| Coexpression | GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_16H_UP | 1.23e-03 | 199 | 28 | 3 | M4278 | |
| Coexpression | GSE360_CTRL_VS_L_DONOVANI_DC_UP | 1.23e-03 | 199 | 28 | 3 | M5143 | |
| Coexpression | GSE37301_LYMPHOID_PRIMED_MPP_VS_RAG2_KO_NK_CELL_UP | 1.23e-03 | 199 | 28 | 3 | M8863 | |
| Coexpression | GSE360_CTRL_VS_L_DONOVANI_MAC_DN | 1.23e-03 | 199 | 28 | 3 | M5159 | |
| Coexpression | GSE1460_CORD_VS_ADULT_BLOOD_NAIVE_CD4_TCELL_DN | 1.23e-03 | 199 | 28 | 3 | M3481 | |
| Coexpression | GSE14308_INDUCED_VS_NATURAL_TREG_DN | 1.25e-03 | 200 | 28 | 3 | M3399 | |
| Coexpression | GSE26343_UNSTIM_VS_LPS_STIM_MACROPHAGE_UP | 1.25e-03 | 200 | 28 | 3 | M8650 | |
| Coexpression | GSE46606_UNSTIM_VS_CD40L_IL2_IL5_3DAY_STIMULATED_IRF4MID_SORTED_BCELL_UP | 1.25e-03 | 200 | 28 | 3 | M9836 | |
| Coexpression | GSE9650_EFFECTOR_VS_MEMORY_CD8_TCELL_DN | 1.25e-03 | 200 | 28 | 3 | M5837 | |
| Coexpression | GSE28726_ACT_CD4_TCELL_VS_ACT_NKTCELL_UP | 1.25e-03 | 200 | 28 | 3 | M8312 | |
| Coexpression | GSE2405_0H_VS_24H_A_PHAGOCYTOPHILUM_STIM_NEUTROPHIL_UP | 1.25e-03 | 200 | 28 | 3 | M6204 | |
| Coexpression | GSE9006_TYPE_1_DIABETES_AT_DX_VS_1MONTH_POST_DX_PBMC_UP | 1.25e-03 | 200 | 28 | 3 | M5783 | |
| Coexpression | GSE23114_PERITONEAL_CAVITY_B1A_BCELL_VS_SPLEEN_BCELL_DN | 1.25e-03 | 200 | 28 | 3 | M8297 | |
| Coexpression | GSE360_DC_VS_MAC_UP | 1.25e-03 | 200 | 28 | 3 | M5172 | |
| Coexpression | GSE22589_HEALTHY_VS_HIV_INFECTED_DC_UP | 1.25e-03 | 200 | 28 | 3 | M7805 | |
| Coexpression | PAL_PRMT5_TARGETS_UP | 1.32e-03 | 204 | 28 | 3 | M10688 | |
| Coexpression | CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP | 1.52e-03 | 54 | 28 | 2 | M15555 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE | 1.53e-03 | 474 | 28 | 4 | M40991 | |
| CoexpressionAtlas | skin | 1.23e-06 | 456 | 27 | 7 | skin | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Flanking Eminence_top-relative-expression-ranked_1000_k-means-cluster#2 | 4.04e-05 | 311 | 27 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Flanking Eminence_1000_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Flanking Eminence_top-relative-expression-ranked_500_k-means-cluster#3 | 9.66e-05 | 192 | 27 | 4 | Facebase_RNAseq_e10.5_Neural Epithelium Flanking Eminence_500_K3 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 8.84e-08 | 180 | 28 | 5 | 44988c34861df359a68376500c42a64fbcc4b431 | |
| ToppCell | normal-na-Lymphocytic_T-T8_naive-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 9.86e-08 | 184 | 28 | 5 | 4a81190b36d197736663e6177d3b76c1cb6282d6 | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.04e-07 | 186 | 28 | 5 | 9a7932d0a208f3997216bd21a72913cc82b59fc9 | |
| ToppCell | 10x5'v1-week_14-16-Hematopoietic-HSC/MPP_and_pro-MEP|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.28e-07 | 194 | 28 | 5 | 7ad255fa357d41fe57ed803314de46a6577a1283 | |
| ToppCell | normal|World / PBMC cell types (v2) per disease, treatment status, and sex | 1.39e-07 | 197 | 28 | 5 | 232e48864aeb5ad6688352383427fb1771986ddc | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.55e-06 | 136 | 28 | 4 | 3e13dc0634f3b05e9f9e6c3193f843f62e603b78 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.55e-06 | 136 | 28 | 4 | 0185486c39700dd2f72d79be6d283494dd8379c9 | |
| ToppCell | facs-Limb_Muscle-ForelimbandHindlimb-24m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.22e-06 | 149 | 28 | 4 | d259e9137109eeb2662022f0915ca463f5bebdfe | |
| ToppCell | 3'|World / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.36e-06 | 186 | 28 | 4 | e265aac37f33947ff6c83f23f8a2c63bbccd60af | |
| ToppCell | severe-Others-CD34+_GATA2+_cells|Others / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.07e-06 | 192 | 28 | 4 | 2e80755627d0350be8976324329e106e808d5574 | |
| ToppCell | droplet-Large_Intestine-COLON:P+D-30m-Epithelial-intestinal_crypt_stem_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.07e-06 | 192 | 28 | 4 | 448b71c965e1b7addc6bccbcd6047cefda3d5b5a | |
| ToppCell | E15.5|World / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 6.07e-06 | 192 | 28 | 4 | 4a0fb4ef8a9281489ffb0881421c9d691c52019c | |
| ToppCell | droplet-Large_Intestine-COLON:P+D-30m-Epithelial-Lgr5+_undifferentiated_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.07e-06 | 192 | 28 | 4 | 5155f746ad57122ef735da776c96721005b8dadc | |
| ToppCell | droplet-Tongue-Unstain-18m-Epithelial-basal_cell|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.20e-06 | 193 | 28 | 4 | 13282e849b11f48085f0840d112a06e896b32cd7 | |
| ToppCell | E12.5|World / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 6.33e-06 | 194 | 28 | 4 | 4b335e4da58de1cd94194dc4208ce83854e5e50a | |
| ToppCell | 10x3'2.3|World / cell types per 3 fetal stages;per 3',per 5' | 6.33e-06 | 194 | 28 | 4 | fc7ed8350ffe1475b8934dfbb107b51991876b0b | |
| ToppCell | NS-critical-LOC-Lymphoid-NKT|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 6.46e-06 | 195 | 28 | 4 | 217e9b096a11adf84400d17403289bee7b351c42 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_T-T4_em-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.46e-06 | 195 | 28 | 4 | 48905d57775ec90cc031af0863cc8c3800f2e48e | |
| ToppCell | 10x3'2.3-week_14-16|World / cell types per 3 fetal stages;per 3',per 5' | 6.46e-06 | 195 | 28 | 4 | 1db4df62578761c1ad49427cd9963540c731f1f2 | |
| ToppCell | normal-na-Lymphocytic_T-T4_naive-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 6.59e-06 | 196 | 28 | 4 | feb1c768cf66c64b6c892905d2d865946e70812f | |
| ToppCell | control-Others-CD34+_GATA2+_cells|Others / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.59e-06 | 196 | 28 | 4 | 25994ca143701c72d2f84a3b6d348fcfa1d26a54 | |
| ToppCell | severe-Lymphocytic-CD4_T_cells_2|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.59e-06 | 196 | 28 | 4 | 1b06639b7d2b81a1e5bcc455f3adda039f42ba57 | |
| ToppCell | Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_monocytic|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.59e-06 | 196 | 28 | 4 | 03de28e1c963e99623e8b0e33bf2e8ef67dc3baa | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_T-T8_naive-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.72e-06 | 197 | 28 | 4 | 284008c2d12d6140919b4b3a694652ab356fc81f | |
| ToppCell | Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_monocytic-leukocyte|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.72e-06 | 197 | 28 | 4 | e621d4f9d4ba5e3ef17d2b477e5e14ea0251147e | |
| ToppCell | Healthy_donor|World / disease group, cell group and cell class (v2) | 6.86e-06 | 198 | 28 | 4 | 1ed0b50c9754727a05c27b21f3546bf2e37eef7f | |
| ToppCell | wk_15-18-Mesenchymal-Fibroblast-Early_fibro|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 6.86e-06 | 198 | 28 | 4 | ecf0a8f2e07f336e23b6f32a2c48d3c7eb66572b | |
| ToppCell | severe-Lymphocytic|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.86e-06 | 198 | 28 | 4 | 7b85f763a5f5fb7bed8e0d702364a2dd18a74f7d | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-HSC/MPP_and_pro|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.86e-06 | 198 | 28 | 4 | a5d66a80bbc1a5aa29d0b763ea9dc3044b8c263d | |
| ToppCell | severe-Lymphocytic-CD4_T_cells_1|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.86e-06 | 198 | 28 | 4 | 2ae52051f7aeaaa4fc739914ac396ba49eaa525d | |
| ToppCell | (5)_Epi_suprabasal|World / Oesophagus cell shreds on cell class (v1) and cell subclass (v1) | 7.00e-06 | 199 | 28 | 4 | e1d0fd71b2f3925d02638413f2155db009f103d9 | |
| ToppCell | Megakaryocytic-erythropoietic-Erythro-cells-Basophilic_Erythroblast|Megakaryocytic-erythropoietic / Lineage, cell class and subclass | 7.00e-06 | 199 | 28 | 4 | 6f159c1215439ec22374903124085746fa8da333 | |
| ToppCell | Enterocyte_Progenitors|World / shred on cell type and cluster | 7.00e-06 | 199 | 28 | 4 | 776bcc887927dea9ebd76ec4338ce2225c319c2c | |
| ToppCell | Skin|World / Skin and Kidney Cells in Lupus Nephritis Patients. | 7.00e-06 | 199 | 28 | 4 | 6be1340413ee868c610b6e3f58c65b493eb22bb5 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T8_naive|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 7.00e-06 | 199 | 28 | 4 | 40eb207fa0f07e2e4d0be69530b8f61f7ea49c73 | |
| ToppCell | Healthy/Control|World / Disease group and Cell class | 7.00e-06 | 199 | 28 | 4 | 2623c42b3e79e401a485879b52e8bbcbc581544d | |
| ToppCell | HSPCs|World / Lineage and Cell class | 7.00e-06 | 199 | 28 | 4 | df1ffc416c6946f1ba182f242a50ee41a571d565 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T8_naive-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 7.00e-06 | 199 | 28 | 4 | 6ed413872301707dc73ae66365bee94cd38a292c | |
| ToppCell | lymphoid-T_cell-CD8+_Naive_T_cell|lymphoid / Lineage, cell class and subclass | 7.00e-06 | 199 | 28 | 4 | 22926327c93ede9f3408c99a0d56e373a33240ef | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-1_mon-Radial_glial-RG|1_mon / Sample Type, Dataset, Time_group, and Cell type. | 7.14e-06 | 200 | 28 | 4 | b3775715b66aee18cff469bf3dbe9c305671c6d6 | |
| ToppCell | Megakaryocytic-erythropoietic-Megakaryo-cells-Megakaryocyte|Megakaryo-cells / Lineage, cell class and subclass | 7.14e-06 | 200 | 28 | 4 | f36023bb369d17b8ec8724616737738e3df01987 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-1_mon-Radial_glial|1_mon / Sample Type, Dataset, Time_group, and Cell type. | 7.14e-06 | 200 | 28 | 4 | 9069e8d3bcc5f44baa00f2abb6cffd87586c3eab | |
| ToppCell | Kidney-Keratinocytes|Kidney / Skin and Kidney Cells in Lupus Nephritis Patients. | 7.14e-06 | 200 | 28 | 4 | 41d83faa9f45ee7ea2ab19be8ecc6d2c5ac7fe5d | |
| ToppCell | Substantia_nigra-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Excitatory_Neuron.Slc17a7.C1ql3_(Hippocampus_Excitatory_Neuron)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 3.06e-05 | 97 | 28 | 3 | 1da964954a95c497ac4a24df1ea3575df5747025 | |
| ToppCell | Substantia_nigra-Neuronal-Excitatory-eN1(Slc17a7)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 3.06e-05 | 97 | 28 | 3 | dd188763ba02337e4f25d56766eda886cffa810d | |
| ToppCell | Substantia_nigra-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 3.06e-05 | 97 | 28 | 3 | a0242258aad0766450ff52fe28278cbb2b8d63a0 | |
| ToppCell | Substantia_nigra-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Excitatory_Neuron.Slc17a7.C1ql3_(Hippocampus_Excitatory_Neuron)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 3.06e-05 | 97 | 28 | 3 | 98a31b9bf0adcad1cb1d803bf7a23d49b4e1f2d5 | |
| ToppCell | Enterocyte-C_02|Enterocyte / shred on cell type and cluster | 8.37e-05 | 136 | 28 | 3 | daf11618c65e8fa2d77001b5c277d534cc012a4b | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-myeloid-myeloid_granulocytic-granulocyte|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 8.74e-05 | 138 | 28 | 3 | d29eb8d361609048e789334a78c51064c296ad2a | |
| ToppCell | Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 9.92e-05 | 144 | 28 | 3 | e2a2f260f5ebaaef46248d199c407a15ce9d024a | |
| ToppCell | facs-MAT-Fat-24m|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.26e-04 | 156 | 28 | 3 | 7433c6d4eb4d061844d8979c1e648d8ed56e1073 | |
| ToppCell | Control-Control-Lymphocyte-T/NK-CD8+_Tcm|Control / Disease, condition lineage and cell class | 1.48e-04 | 165 | 28 | 3 | c55f91c4dc70d5021b4efcc795024eb1681d2564 | |
| ToppCell | TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-4|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 1.51e-04 | 166 | 28 | 3 | 52293b8a74d46e6161fb6a2e7e86e51fd9e89a5b | |
| ToppCell | facs-Tongue-nan-24m-Epithelial-nan|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.59e-04 | 169 | 28 | 3 | 0054f9bfd4d377c7fd94873c1308622051c59a8e | |
| ToppCell | 10x3'2.3-week_14-16-Myeloid_DC-DC-DC_precursor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.71e-04 | 173 | 28 | 3 | a361474ad6f058bb3d3f9671bae697205535090b | |
| ToppCell | facs-Trachea-nan-18m-Epithelial-basal_epithelial_cell_of_tracheobronchial_tree|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.76e-04 | 175 | 28 | 3 | eb87275da6f61ecb4fbc89421dfd27bead1e0f48 | |
| ToppCell | facs-Trachea-nan-18m-Epithelial-nan|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.76e-04 | 175 | 28 | 3 | 3883675a726dd0c6c3a7113d59be2a093ea2dc6f | |
| ToppCell | PBMC-Convalescent|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.76e-04 | 175 | 28 | 3 | d3f897271b64872535213a3dc27b9330255ef9ee | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.0.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.79e-04 | 176 | 28 | 3 | ce85a13e10cf37f5cf38ca8b0bac6701b6d00ffd | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_naive-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.82e-04 | 177 | 28 | 3 | db6de487ef7976b444afadbf3ac60b3259925566 | |
| ToppCell | P03-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.85e-04 | 178 | 28 | 3 | 7975bf0a3146ee0efa4f547af5977e6bf0ba71fd | |
| ToppCell | normal-na-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.85e-04 | 178 | 28 | 3 | fa3585383a1e7da460c88a802aaa81246d681b6b | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-CD8_TCM|Multiple_Sclerosis / Disease, Lineage and Cell Type | 1.85e-04 | 178 | 28 | 3 | cecfda3625e6f9d9bfe47a147efddb63fa3be6df | |
| ToppCell | facs-Bladder-nan-24m-Epithelial|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.89e-04 | 179 | 28 | 3 | fc9f44fb81da0d381a5141a95a005e66a0be28cc | |
| ToppCell | facs-Bladder-nan-24m|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.89e-04 | 179 | 28 | 3 | 9152d92bb96e65d43de54e933494f0d08ae02c4f | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-T8_naive-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.98e-04 | 182 | 28 | 3 | 3a3ed195c15d33d46a2f395cb93018e4bba28353 | |
| ToppCell | E12.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.01e-04 | 183 | 28 | 3 | 523896bd1a93bdda81a009768baa3a1bdbd108b8 | |
| ToppCell | droplet-Skin|droplet / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.08e-04 | 185 | 28 | 3 | 657fd191ed160f8620d57b33820ec7222806f289 | |
| ToppCell | facs-Limb_Muscle-ForelimbandHindlimb|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.08e-04 | 185 | 28 | 3 | eb7d3c1363d5fedc611f9c1a91ea823de251355e | |
| ToppCell | facs-Thymus-Flowthrough-24m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.11e-04 | 186 | 28 | 3 | 202e1514954a5a654f7588bed72cd12db513bb19 | |
| ToppCell | saliva-Severe-critical_progression_d28-40|saliva / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.11e-04 | 186 | 28 | 3 | 0095560ca776b01aa473ad4d6015ed78fc93ff51 | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-HSC/MPP_and_pro-CMP|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.11e-04 | 186 | 28 | 3 | 895905f1d1a01ffd5617a0baa8818693a7e9cb3b | |
| ToppCell | 10x3'2.3-week_17-19-Hematopoietic-HSC/MPP_and_pro-CMP|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.14e-04 | 187 | 28 | 3 | 624e663d5ddc6b8fefbd0e3207bf1928c2478b7b | |
| ToppCell | E15.5-Epithelial-alveolar_epithelial_cell-type_II_pneumocyte|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.14e-04 | 187 | 28 | 3 | 1288fcd0124c70711521f3ac83554e9acdd37cb2 | |
| ToppCell | facs-Large_Intestine-Proximal-24m-Epithelial-intestinal_crypt_stem_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.25e-04 | 190 | 28 | 3 | 933c778bb8ec89621906fe7d484c1d2c6cd28d80 | |
| ToppCell | H1299-infected-SARSCoV1|infected / Cell line, Condition and Strain | 2.25e-04 | 190 | 28 | 3 | f7bfeefc0f30f81710a5ddd979f19b0c910c4a42 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_em-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.25e-04 | 190 | 28 | 3 | f6616b3fe7f4962249503c96c06926240066d861 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_em|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.25e-04 | 190 | 28 | 3 | 1634a6044dce4e026a63976031a498c7460e3dce | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_em-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.25e-04 | 190 | 28 | 3 | 08813c2f9321b82f0ec66854bb7a383aa1171780 | |
| ToppCell | E15.5-Epithelial-epithelial_progenitor_cell|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.32e-04 | 192 | 28 | 3 | cb6f42dcffe650f7958543531d8f5412b2f2eb12 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 2.32e-04 | 192 | 28 | 3 | c4efc170852abbcf0c53c2b0f8a0cc9fe7f116c8 | |
| ToppCell | 10x3'2.3-week_12-13-Hematopoietic-erythroid-early_erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.32e-04 | 192 | 28 | 3 | f29d3d5223fccec3e34ab6582e9503adb14be543 | |
| ToppCell | E12.5-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.32e-04 | 192 | 28 | 3 | 7953a35f7722609d0b197002c8f90fbb156db61b | |
| ToppCell | facs-Spleen-nan-18m|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.32e-04 | 192 | 28 | 3 | 1f81b356520b5506051383d37fae204d59795336 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.32e-04 | 192 | 28 | 3 | 4c9d748f209cc1e13d28c8c7f5180ab8522e0fbf | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-stromal_related|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.32e-04 | 192 | 28 | 3 | 8ad6678df89175c5a4a835c8566f1552df3c996e | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-stromal_related-ICC|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.32e-04 | 192 | 28 | 3 | 2f5378ea0b2fb2f672a36585d375f675983363a1 | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.35e-04 | 193 | 28 | 3 | 739fb2a57772a800a2e94bdd6c71285bb2c162a7 | |
| ToppCell | critical-Myeloid-Resident_Macrophage|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.39e-04 | 194 | 28 | 3 | 0529a990b187a2d875d61e1038821f645ab35a9d | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-CD8_Naive|Multiple_Sclerosis / Disease, Lineage and Cell Type | 2.39e-04 | 194 | 28 | 3 | 42a9a170022f07445a7ee2577707924bbc0269db | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-3_mon|organoid_Paulsen_bioRxiv / Sample Type, Dataset, Time_group, and Cell type. | 2.39e-04 | 194 | 28 | 3 | 4903a0d6e36599bcb83b179462e5b949df9eb685 | |
| ToppCell | control-Myeloid-mDC|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.39e-04 | 194 | 28 | 3 | 9bd075df18970d4577230cd421122f7163245213 | |
| ToppCell | NS-critical-d_16-33-Myeloid-Resident_Macrophage|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.39e-04 | 194 | 28 | 3 | b73e75f973ddfaa8d7e2adb30dbca14076803603 | |
| ToppCell | (1)_Dll4_loss-of-function|World / Stress and Cell class | 2.42e-04 | 195 | 28 | 3 | def4b2350e08a36ffddca71ea80ef611f2d437d9 | |
| ToppCell | (1)_Dll4_loss-of-function-(0)_LMPP_(LSK_cells)|World / Stress and Cell class | 2.42e-04 | 195 | 28 | 3 | f11cf4b6855a26ff6ea572eebaad2aad6bb2434b | |
| ToppCell | droplet-Marrow-BM-1m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.42e-04 | 195 | 28 | 3 | 637b06ef3967b03f7165d102d316e8b7161a817d | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.42e-04 | 195 | 28 | 3 | 003a104daf88ea46fb6c7284f61cc3a02d0311e8 | |
| ToppCell | mild_COVID-19|World / disease group, cell group and cell class (v2) | 2.42e-04 | 195 | 28 | 3 | 6dbe9db5f0e94f2e91b3d1282855d200051ab0ba | |
| ToppCell | ILEUM-inflamed-(1)_T_cell-(1)_Naive_T_cells|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.42e-04 | 195 | 28 | 3 | c82d312ddc3231b0f3c58b2fb74af5dad24948e4 | |
| ToppCell | 10x5'v1-week_14-16-Hematopoietic-HSC/MPP_and_pro-CMP|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 2.46e-04 | 196 | 28 | 3 | f9a7d62684435f7c8a1205e2d0b2af0f6104a2dd | |
| Computational | Genes in the cancer module 32. | 3.47e-09 | 241 | 19 | 8 | MODULE_32 | |
| Computational | Neighborhood of FBL | 1.03e-07 | 140 | 19 | 6 | MORF_FBL | |
| Computational | Neighborhood of RBBP6 | 1.10e-07 | 70 | 19 | 5 | GNF2_RBBP6 | |
| Computational | Neighborhood of G22P1 | 3.51e-07 | 172 | 19 | 6 | MORF_G22P1 | |
| Computational | Neighborhood of APEX1 | 4.35e-07 | 92 | 19 | 5 | GNF2_APEX1 | |
| Computational | Neighborhood of ANP32B | 8.05e-07 | 198 | 19 | 6 | MORF_ANP32B | |
| Computational | Neighborhood of DENR | 1.65e-06 | 51 | 19 | 4 | GNF2_DENR | |
| Computational | Neighborhood of UBE2I | 2.36e-06 | 238 | 19 | 6 | MORF_UBE2I | |
| Computational | Neighborhood of DEK | 4.30e-06 | 264 | 19 | 6 | MORF_DEK | |
| Computational | Neighborhood of FBL | 4.31e-06 | 146 | 19 | 5 | GNF2_FBL | |
| Computational | Neighborhood of NPM1 | 6.65e-06 | 72 | 19 | 4 | GNF2_NPM1 | |
| Computational | Genes in the cancer module 68. | 1.19e-05 | 26 | 19 | 3 | MODULE_68 | |
| Computational | Keratin. | 1.19e-05 | 26 | 19 | 3 | MODULE_298 | |
| Computational | Neighborhood of ACP1 | 2.58e-05 | 211 | 19 | 5 | MORF_ACP1 | |
| Computational | Neighborhood of DAP3 | 4.87e-05 | 119 | 19 | 4 | GNF2_DAP3 | |
| Computational | Neighborhood of EIF3S6 | 5.37e-05 | 122 | 19 | 4 | MORF_EIF3S6 | |
| Computational | Neighborhood of RAN | 8.10e-05 | 268 | 19 | 5 | MORF_RAN | |
| Computational | Neighborhood of BUB3 | 9.47e-05 | 277 | 19 | 5 | MORF_BUB3 | |
| Computational | Genes in the cancer module 322. | 1.43e-04 | 59 | 19 | 3 | MODULE_322 | |
| Computational | Neighborhood of SART1 | 1.74e-04 | 63 | 19 | 3 | MORF_SART1 | |
| Computational | Neighborhood of DDX5 | 1.91e-04 | 65 | 19 | 3 | GCM_DDX5 | |
| Computational | Neighborhood of KPNB1 | 2.69e-04 | 73 | 19 | 3 | GNF2_KPNB1 | |
| Computational | Neighborhood of RAD23A | 2.76e-04 | 348 | 19 | 5 | MORF_RAD23A | |
| Computational | Neighborhood of PCNA | 3.93e-04 | 83 | 19 | 3 | MORF_PCNA | |
| Computational | Neighborhood of CSNK2B | 6.60e-04 | 99 | 19 | 3 | GCM_CSNK2B | |
| Computational | Neighborhood of XRCC5 | 6.66e-04 | 235 | 19 | 4 | MORF_XRCC5 | |
| Computational | Neighborhood of HDAC1 | 8.92e-04 | 254 | 19 | 4 | MORF_HDAC1 | |
| Computational | Neighborhood of NPM1 | 1.05e-03 | 116 | 19 | 3 | GCM_NPM1 | |
| Computational | Neighborhood of EIF3S6 | 1.18e-03 | 121 | 19 | 3 | GNF2_EIF3S6 | |
| Computational | Neighborhood of CSNK2B | 1.40e-03 | 287 | 19 | 4 | MORF_CSNK2B | |
| Computational | Neighborhood of PPP2CA | 1.42e-03 | 129 | 19 | 3 | MORF_PPP2CA | |
| Computational | Neighborhood of TPR | 1.42e-03 | 32 | 19 | 2 | GCM_TPR | |
| Computational | Genes in the cancer module 153. | 1.61e-03 | 34 | 19 | 2 | MODULE_153 | |
| Computational | Neighborhood of TDG | 1.70e-03 | 35 | 19 | 2 | GNF2_TDG | |
| Computational | Neighborhood of EIF4A2 | 1.73e-03 | 138 | 19 | 3 | MORF_EIF4A2 | |
| Computational | Neighborhood of GNB1 | 1.76e-03 | 305 | 19 | 4 | MORF_GNB1 | |
| Computational | Neighborhood of ANP32B | 1.80e-03 | 36 | 19 | 2 | GCM_ANP32B | |
| Computational | Neighborhood of RAD21 | 1.90e-03 | 37 | 19 | 2 | GCM_RAD21 | |
| Computational | Genes in the cancer module 83. | 2.10e-03 | 320 | 19 | 4 | MODULE_83 | |
| Computational | Neighborhood of RAF1 | 2.56e-03 | 43 | 19 | 2 | GCM_RAF1 | |
| Computational | Neighborhood of NPM1 | 2.73e-03 | 162 | 19 | 3 | MORF_NPM1 | |
| Computational | Neighborhood of ELAC2 | 2.93e-03 | 46 | 19 | 2 | GNF2_ELAC2 | |
| Computational | Neighborhood of CTBP1 | 3.02e-03 | 168 | 19 | 3 | MORF_CTBP1 | |
| Computational | Neighborhood of BAG5 | 4.16e-03 | 55 | 19 | 2 | MORF_BAG5 | |
| Computational | Neighborhood of DAP3 | 4.60e-03 | 195 | 19 | 3 | MORF_DAP3 | |
| Computational | Neighborhood of DEK | 4.61e-03 | 58 | 19 | 2 | GNF2_DEK | |
| Computational | Neighborhood of ESPL1 | 5.09e-03 | 61 | 19 | 2 | MORF_ESPL1 | |
| Computational | Neighborhood of SNRP70 | 5.26e-03 | 62 | 19 | 2 | MORF_SNRP70 | |
| Computational | Neighborhood of SMC1L1 | 5.26e-03 | 62 | 19 | 2 | MORF_SMC1L1 | |
| Computational | Neighborhood of ST13 | 5.59e-03 | 64 | 19 | 2 | GNF2_ST13 | |
| Computational | RNA splicing. | 5.76e-03 | 65 | 19 | 2 | MODULE_183 | |
| Computational | Neighborhood of TERF1 | 6.11e-03 | 67 | 19 | 2 | MORF_TERF1 | |
| Computational | Intermediate filaments and MT. | 6.29e-03 | 68 | 19 | 2 | MODULE_438 | |
| Computational | Neighborhood of HBP1 | 6.66e-03 | 70 | 19 | 2 | GCM_HBP1 | |
| Computational | Neighborhood of TPT1 | 6.66e-03 | 70 | 19 | 2 | GCM_TPT1 | |
| Computational | Neighborhood of XRCC5 | 7.61e-03 | 75 | 19 | 2 | GNF2_XRCC5 | |
| Computational | Intermediate filaments. | 7.61e-03 | 75 | 19 | 2 | MODULE_154 | |
| Computational | Intermediate filaments and keratins. | 8.62e-03 | 80 | 19 | 2 | MODULE_357 | |
| Computational | Genes in the cancer module 297. | 8.62e-03 | 80 | 19 | 2 | MODULE_297 | |
| Computational | Neighborhood of EIF3S2 | 8.75e-03 | 246 | 19 | 3 | MORF_EIF3S2 | |
| Computational | Neighborhood of PPP2R5E | 9.25e-03 | 83 | 19 | 2 | MORF_PPP2R5E | |
| Computational | Neighborhood of PSME1 | 9.68e-03 | 85 | 19 | 2 | GCM_PSME1 | |
| Computational | Neighborhood of CCNI | 1.04e-02 | 88 | 19 | 2 | MORF_CCNI | |
| Computational | Neighborhood of UBE2N | 1.20e-02 | 95 | 19 | 2 | MORF_UBE2N | |
| Computational | Neighborhood of SOD1 | 1.22e-02 | 278 | 19 | 3 | MORF_SOD1 | |
| Drug | teleocidin B | 1.17e-12 | 123 | 27 | 8 | CID000072425 | |
| Drug | bromovanin | 1.15e-10 | 127 | 27 | 7 | ctd:C515564 | |
| Drug | sulfur mustard | 1.36e-10 | 130 | 27 | 7 | CID000010461 | |
| Drug | homocysteine thiolactone | 1.43e-10 | 131 | 27 | 7 | CID000107712 | |
| Drug | al-Badry | 7.26e-10 | 165 | 27 | 7 | CID000004545 | |
| Drug | Velcade (bortezomib | 8.32e-09 | 374 | 27 | 8 | CID000093860 | |
| Drug | phenyl isocyanate | 2.97e-08 | 6 | 27 | 3 | ctd:C025319 | |
| Drug | AC1L9MJT | 8.49e-08 | 192 | 27 | 6 | CID000448959 | |
| Drug | butyrate | 1.45e-07 | 767 | 27 | 9 | CID000000264 | |
| Drug | poly(G | 2.13e-07 | 114 | 27 | 5 | CID000439502 | |
| Drug | 1-2q | 9.39e-07 | 289 | 27 | 6 | CID000011820 | |
| Drug | AC1L1AUZ | 1.04e-06 | 157 | 27 | 5 | CID000001160 | |
| Drug | AC1NRA5C | 1.73e-06 | 174 | 27 | 5 | CID005287709 | |
| Drug | AC1L9H5I | 4.27e-06 | 27 | 27 | 3 | CID000444945 | |
| Drug | potassiopotassium | 4.45e-06 | 94 | 27 | 4 | CID006432276 | |
| Drug | [(2R,3R,4R,5S,6R)-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)-3-[(2-tritioacetyl)amino]oxan-4-yl] (3R)-3-hydroxydecanoate | 4.78e-06 | 28 | 27 | 3 | CID011650719 | |
| Drug | polycarbon monofluoride | 1.35e-05 | 5 | 27 | 2 | CID006365488 | |
| Drug | 2,4-diacetylphloroglucinol | 1.91e-05 | 44 | 27 | 3 | CID000016547 | |
| Drug | ClOClO | 2.03e-05 | 6 | 27 | 2 | CID000517862 | |
| Drug | U1-6 | 2.04e-05 | 45 | 27 | 3 | CID006914648 | |
| Drug | ClOO | 2.83e-05 | 7 | 27 | 2 | CID005460593 | |
| Drug | SK&F 83959 | 3.05e-05 | 153 | 27 | 4 | ctd:C080703 | |
| Drug | AC1O59H4 | 3.74e-05 | 55 | 27 | 3 | CID006480473 | |
| Drug | methyl carbonate | 3.78e-05 | 8 | 27 | 2 | CID000012021 | |
| Drug | phenyl saligenin phosphate | 3.95e-05 | 56 | 27 | 3 | CID000104885 | |
| Drug | reverse T | 4.39e-05 | 58 | 27 | 3 | CID000064973 | |
| Drug | Methylmercury Compounds | 4.58e-05 | 851 | 27 | 7 | ctd:D008767 | |
| Drug | AC1Q5S71 | 4.60e-05 | 170 | 27 | 4 | CID000000501 | |
| Drug | butylidenephthalide | 4.63e-05 | 59 | 27 | 3 | ctd:C026105 | |
| Drug | ClOOCl | 6.06e-05 | 10 | 27 | 2 | CID000123287 | |
| Drug | ZD0473 | 6.06e-05 | 10 | 27 | 2 | CID006918325 | |
| Drug | DB08668 | 6.19e-05 | 65 | 27 | 3 | CID011840990 | |
| Drug | U-17 | 6.47e-05 | 66 | 27 | 3 | CID011840991 | |
| Drug | adenosine 3',5'-cyclic phosphate | 6.86e-05 | 907 | 27 | 7 | CID000000274 | |
| Drug | Hexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; HL60; HG-U133A | 7.54e-05 | 193 | 27 | 4 | 1982_DN | |
| Drug | Folic acid [59-30-3]; Down 200; 9uM; HL60; HG-U133A | 8.00e-05 | 196 | 27 | 4 | 1790_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 1000uM; ssMCF7; HG-U133A | 8.16e-05 | 197 | 27 | 4 | 497_DN | |
| Drug | Clomipramine hydrochloride [17321-77-6]; Down 200; 11.4uM; HL60; HG-U133A | 8.32e-05 | 198 | 27 | 4 | 1566_DN | |
| Drug | Sulfisoxazole [127-69-5]; Down 200; 15uM; HL60; HG-U133A | 8.32e-05 | 198 | 27 | 4 | 1603_DN | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; HL60; HG-U133A | 8.49e-05 | 199 | 27 | 4 | 2024_DN | |
| Drug | Chloroquine diphosphate [50-63-5]; Down 200; 7.8uM; HL60; HG-U133A | 8.49e-05 | 199 | 27 | 4 | 1719_DN | |
| Drug | propyzamide | 8.87e-05 | 12 | 27 | 2 | CID000032154 | |
| Drug | K 2S | 1.05e-04 | 13 | 27 | 2 | CID000014800 | |
| Drug | naphthalene acetic acid | 1.07e-04 | 78 | 27 | 3 | CID000006862 | |
| Drug | 3-deoxy-3-fluoro-D-glucose | 1.41e-04 | 15 | 27 | 2 | CID000450201 | |
| Drug | phorbol acetate myristate | 1.54e-04 | 1399 | 27 | 8 | CID000004792 | |
| Drug | bilirubin-phosphate | 1.61e-04 | 16 | 27 | 2 | CID005497144 | |
| Drug | K-11 | 1.82e-04 | 17 | 27 | 2 | CID000469667 | |
| Drug | AC1L1GT5 | 1.91e-04 | 95 | 27 | 3 | CID000003829 | |
| Drug | AC1L9LFK | 2.29e-04 | 19 | 27 | 2 | CID000447957 | |
| Drug | AC1L2IND | 2.29e-04 | 19 | 27 | 2 | CID000021585 | |
| Drug | AC1NPJ0T | 2.54e-04 | 20 | 27 | 2 | CID005159168 | |
| Drug | 2c5o | 3.32e-04 | 284 | 27 | 4 | CID000447956 | |
| Drug | AC1L1AVT | 3.37e-04 | 23 | 27 | 2 | CID000001170 | |
| Drug | EMD 57033 | 3.37e-04 | 23 | 27 | 2 | CID000187079 | |
| Drug | NSC333308 | 3.45e-04 | 116 | 27 | 3 | CID000000152 | |
| Drug | potassium hydride | 4.60e-04 | 128 | 27 | 3 | CID000082127 | |
| Drug | olomoucine II | 4.67e-04 | 27 | 27 | 2 | CID005494414 | |
| Drug | Bi-E | 4.67e-04 | 27 | 27 | 2 | CID006914595 | |
| Drug | C15873 | 4.67e-04 | 27 | 27 | 2 | CID000045749 | |
| Drug | ethylnylestradiol | 5.00e-04 | 1251 | 27 | 7 | CID000003285 | |
| Drug | 4-nitrobiphenyl | 5.02e-04 | 28 | 27 | 2 | CID000007114 | |
| Drug | NH(2 | 5.39e-04 | 29 | 27 | 2 | CID005460607 | |
| Drug | AC1NQZM2 | 5.39e-04 | 29 | 27 | 2 | CID005282177 | |
| Drug | dinophysistoxin-1 | 6.17e-04 | 31 | 27 | 2 | CID006437058 | |
| Drug | AC1NBTRA | 6.57e-04 | 32 | 27 | 2 | CID004473609 | |
| Drug | A-skin | 6.57e-04 | 32 | 27 | 2 | CID000208772 | |
| Drug | dichlorprop | 6.99e-04 | 33 | 27 | 2 | CID000008427 | |
| Drug | EMCs | 7.42e-04 | 34 | 27 | 2 | CID005091655 | |
| Drug | Eledoisinum | 7.42e-04 | 34 | 27 | 2 | CID000006242 | |
| Drug | Topo | 7.73e-04 | 153 | 27 | 3 | CID000065577 | |
| Drug | Physalemin | 7.87e-04 | 35 | 27 | 2 | CID000017268 | |
| Drug | NPLA | 7.87e-04 | 35 | 27 | 2 | CID000004387 | |
| Drug | mantATP | 7.87e-04 | 35 | 27 | 2 | CID000123756 | |
| Drug | H atom | 7.88e-04 | 154 | 27 | 3 | CID005362549 | |
| Drug | 2gg8 | 8.79e-04 | 37 | 27 | 2 | CID006914647 | |
| Drug | (3S,4R,5R)-5-methylolpiperidine-2,3,4-triol | 8.79e-04 | 37 | 27 | 2 | CID010197840 | |
| Drug | I5B1 | 8.79e-04 | 37 | 27 | 2 | CID005487705 | |
| Drug | Dichlororibofuranosylbenzimidazole | 9.27e-04 | 38 | 27 | 2 | ctd:D004004 | |
| Drug | Metribolone | 1.01e-03 | 382 | 27 | 4 | ctd:D015741 | |
| Drug | Phenytoin | 1.04e-03 | 385 | 27 | 4 | ctd:D010672 | |
| Drug | 4-vinyl-1-cyclohexene dioxide | 1.05e-03 | 170 | 27 | 3 | ctd:C012606 | |
| Drug | Nb d | 1.12e-03 | 174 | 27 | 3 | CID000445938 | |
| Drug | NU1025 | 1.13e-03 | 42 | 27 | 2 | CID000063306 | |
| Drug | Roxarsone | 1.13e-03 | 42 | 27 | 2 | ctd:D012406 | |
| Disease | myopathy (implicated_via_orthology) | 1.05e-07 | 48 | 27 | 4 | DOID:423 (implicated_via_orthology) | |
| Disease | frontotemporal dementia (implicated_via_orthology) | 1.49e-07 | 12 | 27 | 3 | DOID:9255 (implicated_via_orthology) | |
| Disease | neurodegenerative disease (implicated_via_orthology) | 1.98e-07 | 145 | 27 | 5 | DOID:1289 (implicated_via_orthology) | |
| Disease | Amyotrophic Lateral Sclerosis | 2.28e-07 | 58 | 27 | 4 | C0002736 | |
| Disease | Keratosis of Greither | 8.06e-07 | 2 | 27 | 2 | C2936837 | |
| Disease | cinnamaldehyde measurement | 8.06e-07 | 2 | 27 | 2 | EFO_0021839 | |
| Disease | Palmoplantar keratoderma, epidermolytic | 8.06e-07 | 2 | 27 | 2 | cv:C1721006 | |
| Disease | Keratoderma, Palmoplantar, Epidermolytic | 2.42e-06 | 3 | 27 | 2 | C1721006 | |
| Disease | Epidermolytic palmoplantar keratoderma Vorner type | 2.42e-06 | 3 | 27 | 2 | C2931735 | |
| Disease | amyotrophic lateral sclerosis type 6 (implicated_via_orthology) | 2.42e-06 | 3 | 27 | 2 | DOID:0060198 (implicated_via_orthology) | |
| Disease | Epidermolytic palmoplantar keratoderma of Vorner | 2.42e-06 | 3 | 27 | 2 | C0343110 | |
| Disease | amyotrophic lateral sclerosis (implicated_via_orthology) | 2.73e-06 | 30 | 27 | 3 | DOID:332 (implicated_via_orthology) | |
| Disease | autosomal dominant limb-girdle muscular dystrophy type 3 (implicated_via_orthology) | 1.21e-05 | 6 | 27 | 2 | DOID:0110306 (implicated_via_orthology) | |
| Disease | Frontotemporal Dementia With Motor Neuron Disease | 2.25e-05 | 8 | 27 | 2 | C3888102 | |
| Disease | Adenocarcinoma of lung (disorder) | 3.57e-05 | 206 | 27 | 4 | C0152013 | |
| Disease | Keratoderma, Palmoplantar | 9.60e-05 | 16 | 27 | 2 | C4551675 | |
| Disease | Amyotrophic lateral sclerosis | 1.09e-04 | 17 | 27 | 2 | cv:C0002736 | |
| Disease | Amyotrophic Lateral Sclerosis With Dementia | 3.22e-04 | 29 | 27 | 2 | C0393554 | |
| Disease | Amyotrophic Lateral Sclerosis, Guam Form | 3.69e-04 | 31 | 27 | 2 | C0543859 | |
| Disease | amyotrophic lateral sclerosis (is_implicated_in) | 3.93e-04 | 32 | 27 | 2 | DOID:332 (is_implicated_in) | |
| Disease | internet addiction disorder | 4.18e-04 | 33 | 27 | 2 | EFO_0803368 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GAGGRGGGAGRGGAG | 116 | B3EWF7 | |
| FGRGGNFSGRGGFGG | 216 | Q32P51 | |
| NFGGGRGGGFGGNDN | 156 | A0A2R8Y4L2 | |
| FGRGGNFSGRGGFGG | 171 | A0A2R8Y4L2 | |
| GGFGGSRGGGGYGGS | 181 | A0A2R8Y4L2 | |
| GGDRGGGYGGDRGGG | 456 | Q92804 | |
| GDRSGGGYGGDRGGG | 551 | Q92804 | |
| FGGGRGVGSGFGGAG | 106 | Q01546 | |
| LGGGFGGGSRGFGGA | 86 | P35527 | |
| GGGGSGGYGQQDRGG | 201 | P35637 | |
| SGGGGGGGGGGYNRS | 221 | P35637 | |
| GRGGGGGGFRGFSSG | 11 | P35908 | |
| GGFGAAGGFGGRGGG | 81 | P35908 | |
| AGGFGGRGGGFGGGS | 86 | P35908 | |
| GRGGGFGGGSSFGGG | 91 | P35908 | |
| GGRGMGGGFGGAGGF | 111 | P12035 | |
| AGGGSGSGFGRGGGG | 556 | P12035 | |
| GSGFGRGGGGGIGGG | 561 | P12035 | |
| RGGGGGIGGGFGGGS | 566 | P12035 | |
| RFGAGAGGGYGFGGG | 86 | P13647 | |
| GGGGSFGAGGGFGSR | 51 | P04264 | |
| ARGGGRGSGFGGGYG | 81 | P04264 | |
| GRGGFGGGRGRGGGF | 26 | P22087 | |
| RGRGRGGGGGGGGGG | 41 | P22087 | |
| DGLGGYGRGGGGSGG | 316 | P31942 | |
| GAGGGGGRGGRGNGA | 26 | Q9UMN6 | |
| GGFGGRGGGRGGFGG | 651 | P19338 | |
| GGFGGRGGGRGGRGG | 661 | P19338 | |
| GGRGGFGGRGRGGFG | 671 | P19338 | |
| FGGRGRGGFGGRGGF | 676 | P19338 | |
| GGGRGQGGRGRGGGF | 536 | Q06787 | |
| ARGGGGGGGGDGGGR | 36 | Q9NQS1 | |
| GGGRGGFQGRGDYGG | 381 | Q52LJ0 | |
| SGGGGYGNSRGFGGG | 621 | O15523 | |
| NRGGGGFRGRGGGGG | 611 | Q9BUJ2 | |
| GGGSGGGGNYRGGFN | 646 | Q9BUJ2 | |
| GGRGGFNRGGGGGGF | 6 | Q9NY12 | |
| SNHFRGGGGGGGGGN | 26 | Q9NY12 | |
| GGGGNFRGGGRGGFG | 36 | Q9NY12 | |
| GGGGRGGGRGGGFRG | 181 | Q9NY12 | |
| GGGRGGGFRGGRGGG | 186 | Q9NY12 | |
| GGFRGGRGGGGGGFR | 191 | Q9NY12 | |
| GRGGGGGGFRGGRGG | 196 | Q9NY12 | |
| GGFGNQGGFGNSRGG | 281 | Q13148 | |
| GAFGYGNGGGVGGGA | 301 | P0DPA2 | |
| GGGGGGGGGHGEYLQ | 21 | Q02447 | |
| GNFMGRGGNFGGGGG | 221 | P51991 | |
| RGGNFGGGGGNFGRG | 226 | P51991 | |
| GGGGGNFGRGGNFGG | 231 | P51991 | |
| NFGRGGNFGGRGGYG | 236 | P51991 | |
| GNFGGRGGYGGGGGG | 241 | P51991 | |
| GGGGGGGGGRRNATG | 91 | Q8N1X5 | |
| NFGGGRGGGFGGNDN | 201 | P09651 | |
| FGRGGNFSGRGGFGG | 216 | P09651 | |
| GGFGGSRGGGGYGGS | 226 | P09651 | |
| GGFGGGSGSNFGGGG | 296 | P09651 | |
| GPGMGNRGGFRGGFG | 16 | P15880 | |
| GFCQGGGVGGFGGGR | 81 | Q7Z794 | |
| GGVGGFGGGRGFGVG | 86 | Q7Z794 | |
| RGRSGGGYGSGCGGG | 531 | Q7Z794 |